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 Abstract 
Muscle satellite cells are the primary stem cells of postnatal skeletal muscle. Quiescent 
satellite cells become activated and proliferate during muscle regeneration after injury. They 
have the ability to adopt two divergent fates: differentiation or self-renewal. The Notch pathway 
is a critical regulator of satellite cell activation and differentiation. Notch signaling is activated 
upon the interaction of a Notch ligand present in a signal-sending cell with a Notch receptor 
present in a signal-receiving cell. Delta-like 1 (Dll1) is a mammalian ligand for Notch receptors. 
In this study, we found that Notch activity is essential for maintaining the expression of Pax7, a 
transcription factor associated with self-renewing satellite cells. We also demonstrated that Dll1 
represents a substrate for several ADAM metalloproteases. Dll1 shedding takes place in a pool of 
Pax7-positive self-renewing cells, but Dll1 remains intact in differentiated myotubes. Inhibition 
of Dll1 shedding with a dominant-negative form of ADAM12 leads to elevated Notch signaling, 
inhibition of differentiation and expansion of the pool of self-renewing cells. We propose that 
ADAM-mediated shedding of Dll1 helps achieve an asymmetry in Notch signaling in initially 
equivalent myogenic cells and helps sustain the balance between differentiation and self-renewal. 
Pax7 plays a key role in protecting satellite cells from apoptosis. The mechanism of Pax7 
protecting muscle satellite cells from apoptosis is not well understood. In the second part of this 
study, we show that Pax7 up-regulates manganese superoxide dismutase (MnSOD) at the 
transcriptional level, suggesting the involvement of MnSOD in Pax7-mediated cell survival. 
A specific chromosomal translocation involving the Pax7 gene and generation of a fusion 
protein Pax7-FKHR is found a childhood cancer, rhabdomyosarcoma. Furthermore, the level of 
the wild-type Pax7 is down-regulated in rhabdomyosarcomas. In the third part of this 
dissertation, we investigated the dominant-negative effect of Pax7-FKHR fusion protein on the 
wild-type Pax7, and found that the Pax7 protein level is down-regulated by Pax7-FKHR 
expression while the Pax7 mRNA level is not affected. We propose a specific microRNA-
mediated inhibition of Pax7 mRNA translation by the oncogenic Pax7-FKHR fusion protein. 
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 Abstract 
M
P
uscle satellite cells are the primary stem cells of postnatal skeletal muscle. Quiescent 
satellite cells become activated and proliferate during muscle regeneration after injury. They 
have the ability to adopt two divergent fates: differentiation or self-renewal. The Notch pathway 
is a critical regulator of satellite cell activation and differentiation. Notch signaling is activated 
upon the interaction of a Notch ligand present in a signal-sending cell with a Notch receptor 
present in a signal-receiving cell. Delta-like 1 (Dll1) is a mammalian ligand for Notch receptors. 
In this study, we found that Notch activity is essential for maintaining the expression of Pax7, a 
transcription factor associated with self-renewing satellite cells. We also demonstrated that Dll1 
represents a substrate for several ADAM metalloproteases. Dll1 shedding takes place in a pool of 
Pax7-positive self-renewing cells, but Dll1 remains intact in differentiated myotubes. Inhibition 
of Dll1 shedding with a dominant-negative form of ADAM12 leads to elevated Notch signaling, 
inhibition of differentiation and expansion of the pool of self-renewing cells. We propose that 
ADAM-mediated shedding of Dll1 helps achieve an asymmetry in Notch signaling in initially 
equivalent myogenic cells and helps sustain the balance between differentiation and self-renewal. 
ax7 plays a key role in protecting satellite cells from apoptosis. The mechanism of Pax7 
protecting muscle satellite cells from apoptosis is not well understood. In the second part of this 
study, we show that Pax7 up-regulates manganese superoxide dismutase (MnSOD) at the 
transcriptional level, suggesting the involvement of MnSOD in Pax7-mediated cell survival. 
A specific chromosomal translocation involving the Pax7 gene and generation of a fusion 
protein Pax7-FKHR is found a childhood cancer, rhabdomyosarcoma. Furthermore, the level of 
the wild-type Pax7 is down-regulated in rhabdomyosarcomas. In the third part of this 
dissertation, we investigated the dominant-negative effect of Pax7-FKHR fusion protein on the 
wild-type Pax7, and found that the Pax7 protein level is down-regulated by Pax7-FKHR 
expression while the Pax7 mRNA level is not affected. We propose a specific microRNA-
mediated inhibition of Pax7 mRNA translation by the oncogenic Pax7-FKHR fusion protein. 
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CHAPTER 1 
 
INTRODUCTION 
 1
Muscle Satellite Cells 
A
S
dult skeletal muscle is composed of myofibers, which are highly specialized syncytia 
sustained by hundreds of post-mitotic myonuclei. Muscle satellite cells are mononucleated 
precursor cells that are defined by their position beneath the basal lamina of myofibers (Mauro, 
1961; Yablonka-Reuveni, 1995). Satellite cells are the primary source for the postnatal muscle 
growth (Bischoff and Heintz, 1994). Upon injury, the activation and proliferation of satellite 
cells is responsible for the efficient repair and regeneration of damaged skeletal muscle (Whalen 
et al., 1990). 
 
Quiescence, Activation and Self-renewal of Satellite cells 
atellite cells are quiescent under normal conditions in the adult muscle. Quiescent satellite 
cells are arrested at G0 stage of the cell cycle. They express a variety of signature proteins 
including CD34, M-cadherin, Pax7, syndecan-3, syndecan-4 and c-met (Beauchamp et al., 2000; 
Seale et al., 2000; Cornelison et al., 2000). FoxO and Rb families of transcriptional regulators, 
which promote quiescence in various cells, may also contribute to the reversible quiescent state 
of satellite cells (Yusuf and Fruman, 2003). A metalloprotease disintegrin, ADAM12 has been 
reported to up-regulate quiescence markers, retinoblastoma-related protein p130 and cell cycle 
inhibitor p27, and induce a quiescent-like phenotype in C2C12 myoblasts (Cao et al., 2003). The 
satellite cell niche, which is beneath the basal lamina of myofibers, is crucial for its maintenance 
of quiescence. 
The activation of satellite cells from quiescent state and progression into proliferation and 
differentiation is controlled by various transcription factors. Myogenic regulatory factors (MRFs) 
play essential roles during satellite cell activation. This family includes myogenic determination 
factor 1 (MyoD), myogenic factor 5 (Myf5), myogenin and myogenic regulatory factor 4 (Mrf4) 
(Ludolph and Konieczny, 1995). Upon activation, satellite cells differentially express Myf5 
(Beauchamp et al. 2000; Kuang et al., 2007). It has been further proposed that the Myf5 gene 
activity represents committed progenitors, whereas Myf5-absent cells contribute to the satellite 
cell reservoir (Kuang et al., 2007). MyoD expression appears during satellite cell activation and 
proliferation. The absence of MyoD impairs muscle regeneration (Megeney et al., 1996), delays 
the onset of myoblast differentiation and increases the propensity for self-renewal (Sabourin et 
al., 1999; Yablonka-Reuveni et al., 1999). Myogenin is essential for muscle satellite cell 
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differentiation (Hasty et al., 1993). It has been reported that over-expression of myogenin results 
in down-regulation of the satellite cell marker, Pax7 (Olguin et al., 2007). 
A
T
S
P
fter satellite cell activation, the satellite cell pool is maintained via self-renewal, which 
involves withdrawal from the myogenic differentiation program. During muscle regeneration 
after injury, satellite cells are activated and proliferate. This is accompanied by co-expression of 
Pax7 and MyoD. Some of the cells then down-regulate Pax7, maintain MyoD and differentiate to 
produce myofibers (Halevy et al., 2004; Zammit et al., 2004), whereas others down-regulate 
MyoD expression while maintaining Pax7 and become quiescent to renew the satellite cell pool 
(Fig.1-1) (Zammit et al., 2004). 
wo models have been proposed for satellite cell self-renewal, “asymmetric cell division 
model” and “stochastic cell fate model” (Dhawan and Rando, 2005). In “asymmetric cell 
division model”, after satellite cell activation, an asymmetric division occurs during the first cell 
division, with one daughter cell returning to quiescence and forming a new satellite cell, while 
the other daughter cell undergoing proliferation and further generating fusion-competent 
myoblasts. In “stochastic cell fate model”, the progeny of activated satellite cells are generated 
by symmetric cell divisions. At some point, one or more progeny adopts a different fate, returns 
to quiescence and forms a new satellite cell, while the remainders differentiate. The Notch 
inhibitor, Numb, is distributed asymmetrically during satellite cell division, which supports the 
asymmetric hypothesis in satellite cell self-renewal (Conboy and Rando, 2002). 
atellite cells are commonly identified by expression of the paired box transcription factor, 
Pax7. Pax7 plays an essential role in satellite cell maintenance and survival. Notch signaling is 
implicated in several steps of satellite cell proliferation, differentiation and self-renewal. The 
main focus of this dissertation is the modulation of Notch signaling in maintaining the balance 
between satellite cell differentiation and self-renewal, and the mechanism of Pax7 in protecting 
muscle satellite cells from apoptosis. In addition, a Pax7-related childhood cancer, 
rhabdomyosarcoma is also investigated. 
 
Pax7 in Myogenesis and Rhabdomyosarcoma 
Pax Genes 
ax genes encode a family of transcription factors that play key roles in tissue and organ 
formation during embryonic development. Pax proteins can be divided into four groups based on 
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their structures (Fig.1-2). All Pax proteins possess a paired domain, which is the defining 
characteristic of the family. The paired domain was originally identified in Drosophila Paired 
protein (Bopp et al., 1986; Treisman et al., 1991) and contains two sub-domains, PAI and RED. 
The N-terminal PAI domain binds to DNA directly. The consensus DNA binding site for paired 
domain is (G/T)T(T/C)(C/A)(C/T)(G/C)(G/C) with different nucleotide preferences of different 
members (Czerny et al., 1993; Epstein et al., 1994; Jun and Desplan, 1996). An eight-amino acid 
octapeptide is another conserved motif found in most of the Pax proteins with the exceptions of 
Pax4 and Pax6. The consensus sequences are HSIDGIL(G/S) for Pax3 and Pax7, 
YSI(N/S)G(I/L)LG for Pax2, Pax5 and Pax8 and HSV(S/T)(N/D)ILG for Pax1 and Pax9 (Noll, 
1993). The octapeptide has transcriptional inhibitory function through interaction with other 
proteins to form repressor complexes (Smith, 1996). Several Pax proteins have a three helixed 
(Pax3, Pax4, Pax6 and Pax7), or a partial one helixed (Pax2, Pax5 and Pax8) homeodomain. The 
homeodomains share a conserved helix-turn-helix secondary structure. The homeodomains of 
Pax proteins contribute to DNA binding by recognizing the palindromic elements of TAAT(N)2-
3ATTA (Wilson et al., 1993). 
Pax proteins play important roles during organogenesis, and their expression is tightly 
regulated spatially and temporally. Examples of Pax protein expression during tissue and organ 
development are Pax1 and Pax9 in skeleton (Wilm et al., 1998; Peters et al., 1999), Pax2, Pax3, 
Pax5, Pax6, Pax7 and Pax8 in central nervous system (Epstein et al., 1991; Stoykova et al., 
1994), Pax2 and Pax8 in kidney (Dressler et al., 1993), Pax5 in B-cells (Nutt et al., 1999), Pax8 
in thyroid (Mansouri et al., 1998), Pax4 and Pax6 in pancreas (Sosa-Pineda et al., 1997; St-Onge 
et al., 1997) and Pax3 and Pax7 in skeletal muscle (Tajbakhsh and Buckingham, 2000; Ben-Yair 
and Kalcheim, 2005; Gros et al., 2005). 
Pax proteins are essential for growth and progression of cancers. The persistent 
expression of specific Pax proteins characterizes several tumors. Pax2 is frequently expressed in 
a number of primary human cancers, including brain, breast, colon, lung, lymphoma, melanoma, 
ovary and prostate cancers. Ovarian and bladder cancer cell lines depend on Pax2 for survival 
(Muratovska et al., 2003). It has been reported that melanoma cell lines depend on Pax3 for 
survival (Margue et al., 2000). Pax3 and Pax7 are commonly over-expressed in embryonal 
rhabdomyosarcoma (ERM) (Bernasconi et al., 1996; Barr, 1999; Tiffin et al., 2003). Pax5 is 
expressed in a variety of hematological malignancies, including follicular and non-Hodgkin’s 
 
lymphoma (Krenacs et al., 1998). Over-expression of Pax6 leads to cystic adenoma development 
and also occurs in the exocrine pancreas and intestine tumors (Salem et al., 2000). Pax8 is 
expressed in most thyroid cancers and expression of Pax8 correlates with a greater risk of tumor 
reoccurrence (Macchia et al., 1998; Castro et al., 2006). Furthermore, Pax genes are associated 
with specific chromosomal translocations in several tumors. In alveolar rhabdomyosarcoma 
(ARM), chromosomal translocations involving Pax3 or Pax7 genes, and fusion with the forkhead 
transcription factor (FKHR) gene, create oncogenic fusion proteins Pax3-FKHR or Pax7-FKHR 
(Barr et al., 1993; Galili et al., 1993; Shapiro et al., 1993; Davis et al., 1994). In a subset of 
lymphoplasmacytoid lymphoma, the Pax5 gene is involved in translocation and fusion with the 
immunoglobulin heavy chain (IGH) gene, which produces an oncogenic fusion protein Pax5-
IGH (Busslinger et al., 1996; Iida et al., 1996). Pax8 is involved in chromosomal translocation 
and fusion with the peroxisome proliferator-activated receptor γ (PPARγ) gene to form an 
oncogenic fusion protein Pax8-PPARγ in thyroid tumors (Kroll et al., 2000; Cheung et al., 2003). 
 
Pax7 and Pax3 in Myogenesis and Rhabodomysarcoma 
P
A
ax7 and Pax3 belong to the group III of Pax proteins, which contain a paired domain, an 
octapeptide, and a homeodomain with three α-helices. Binding to a target DNA occurs through 
the N-terminal paired domain and the homeodomain (Jun and Desplan, 1996). The 
transactivation domain includes a proline-, threonine- and serine-rich region and the C-terminus 
of Pax3/7 proteins (Jostes et al., 1990; Seo et al., 1998). Pax3 and Pax7 are partially overlapped 
in their expression during development. They are both expressed in dorsal neural tube and play 
essential roles in the development of neural crest cells (NCCs) (Kalcheim and Le Douarin, 
1986). They are also expressed during skeletal muscle development and play critical roles in 
myogenesis. 
 population of cells that express Pax3 and Pax7 but no other skeletal muscle specific 
markers was identified to constitute the resident muscle progenitor cells that subsequently 
become myogenic and form skeletal muscle in mouse embryos (Kassar-Duchossoy et al., 2005; 
Relaix et al. 2005). Pax3 and Pax7 are upstream regulators of the myogenic program 
(Buckingham, 2006). Pax3 and Pax7 regulate the expression of myogenic regulatory factors, 
MyoD and Myf5 (Relaix et al., 2006; Bajard et al., 2006). In the absence of both Pax7 and Pax3, 
skeletal muscle development is defective (Relaix et al. 2005). During embryonic muscle 
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development, both Pax7 and Pax3 function to ensure cell survival (Seale et al., 2000). The anti-
apoptotic function of Pax7 is predominant in muscle satellite cells and cannot be replaced by its 
paralogue, Pax3 (Relaix et al., 2006). 
B
T
oth Pax3 and Pax7 are involved in a childhood cancer, rhabdomyosarcoma. 
Rhabdomyosarcoma (RMS) is a highly malignant soft tissue tumor developed in children and 
young adults. Its two main subtypes are embryonal rhabdomyosarcoma (ERM) and alveolar 
rhabdomyosarcoma (ARM), with ARM being the more aggressive subtype (Tsokos et al., 1992). 
Approximately 70% of ARMs have one of the two specific chromosomal translocations 
occurring on chromosome 1 or 2 with chromosome 13 (Turc-Carel et al., 1986; Douglass et al., 
1987; Wang-Wuu et al., 1988). The chromosomal translocation connects the 5’-end of the Pax3 
or Pax7 gene to the 3’-end of the FKHR gene, and generates a fusion protein with the Pax3 or 
Pax7 DNA binding domain and the FKHR transcriptional activation domain (Fig.1-3) (Barr et 
al., 1993; Galili et al., 1993; Shapiro et al., 1993; Davis et al., 1994). The fusion proteins are 
more potent transcriptional activators than the wild-type Pax3 or Pax7 (Bennicelli et al., 1995; 
Scheidler et al., 1996). Studies of ARM tumors revealed that the wild-type Pax3 is up-regulated 
in ARM and its up-regulation is independent of fusion proteins, whereas the wild-type Pax7 is 
down-regulated in fusion positive ARM tumors (Tiffin et al., 2003; Tomescu et al., 2004). This 
indicates that fusion proteins may have a dominant negative effect on the wild-type Pax7. 
 
Alternative Splicing of Pax7 
he Pax7 gene consists of nine exons. Exons 2, 3 and 4 encode the paired domain. The 
homeodomain is encoded by exons 5 and 6. The transactivation domain is encoded by exons 6, 7 
and 8 (Vorobyov et al., 1997; Barr et al., 1999). As a result of alternative splicing which occurs 
at the intron 2/exon 3 junction and the intron 3/exon 4 junction, alternate Pax7 transcripts include 
or exclude a tri-nucleotide, CAG, and a hexa-nucleotide, GTTTAG, respectively (Ziman and 
Kay, 1998). This produces four Pax7 isoforms a-d (Q+GL+, Q+GL-, Q-GL+, Q-GL-) with the 
inclusion or exclusion of a glutamine (Q) and a glycine-leucine dipeptide (GL), respectively. The 
various isoforms contain distinct tertiary structures and have different DNA binding affinities 
and specificities (Du et al., 2005). Another type of alternative splicing of Pax7 adds more 
complexity. Transcripts of Pax7 with alternative 3’-ends have been identified in both human and 
mice (Barr et al., 1999; Seale et al., 2000). Transcript Pax7A contains exons one through eight, 
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while transcript Pax7B contains exons one through nine. The alternative products encode 
proteins with distinct C-termini, which indicate different transactivation activity. Varied 
expression levels of alternative Pax7 transcripts have been reported in embryonic and adult 
muscles (Ziman et al., 1997; Lamey et al., 2004). 
 
Pax7 in Satellite Cells 
P
N
ax7 has attracted particular attention in regulation of muscle satellite cells since it was 
reported that Pax7-deficient mice completely lack muscle satellite cells (Seale et al., 2000). 
However, it has been later shown that muscles of juvenile Pax7-null mice at P11 contain a 
reduced but substantial number of satellite cells. The number of satellite cells declined strongly 
during postnatal development. Muscle growth and regeneration was greatly compromised in 
Pax7-deficient mice (Oustanina et al., 2004). This implicates Pax7 in maintenance of muscle 
satellite cells and regeneration of skeletal muscle during postnatal growth (Oustanina et al., 
2004; Kuang et al., 2006). Pax7 has a critical anti-apoptotic function in activated satellite cells, 
for which its paralogue, Pax3 cannot compensate. This explains the progressive satellite cell 
death in Pax7-deficient mice postnatally (Relaix et al., 2006). However, the mechanism of Pax7-
mediated satellite cell survival is not clear. Pax7 can activate transcription in quiescent satellite 
cells and influence satellite cell fate by controlling the expression of myogenic regulatory factors 
(Zammit et al., 2006). Pax7 modulates the expression of Myf5 by interacting with Wdr5 and 
Ash2L, the core proteins of histone methyltransferase complex (McKinnell et al., 2008). Pax7 
transcriptional activity is required for MyoD expression (Relaix et al., 2006). Constitutive 
expression of Pax7 delays the induction of myogenin expression in satellite cells (Zammit et al., 
2006), whereas over-expression of myogenin results in down-regulation of Pax7 (Olguin et al., 
2007). 
 
Notch, Delta and ADAM12 
Notch Signaling 
otch is the receptor of an evolutionally conserved signaling pathway that regulates cell 
fate decision and differentiation. Notch was discovered first in Drosophila, where mutation in 
the Notch gene resulted in notches in their wingblades. 
 7
TIn
he Notch genes encode a family of type I single transmembrane proteins. In mammals, 
Notch is presented to a ligand as a heterodimer produced as a result of processing at S1 site by a 
furin-like convertase in the trans-Golgi, during the secretion process (Logeat et al., 1998; 
Nichols et al., 2007). The extracellular region of Notch includes 10 to 36 epidermal growth 
factor (EGF)-like repeats, three juxtamembrane repeats (also known as Lin-12 repeats) and the 
heterodimerization domains (Wharton et al., 1985; Yochem et al., 1988). Heterodimerization 
domains hold the Notch extracellular domain (NECD) with the Notch membrane-tethered 
intracellular domain non-covalently (Sanchez-Irizarry et al., 2004). The intracellular region of 
Notch is composed of the RBPjκ Associate Molecule (RAM) region, repeated structural motifs 
named Ankyrin repeats, a proline-, glutamine-, serine-, threonine-rich (PEST) domain, and a 
transactivation domain (TAD). Ankyrin repeats are flanked by nuclear localization signals 
(Fleming 1998; Lubman et al., 2004). They mediate the interaction between Notch and CSL 
DNA binding proteins. The PEST domain is involved in the degradation of Notch (Fig.1-4, right 
panel) (Fryer et al., 2004). 
 the canonical Notch signaling pathway, activation of Notch requires the interaction 
between a DSL (Delta and Serrate in Drosophila, Lag2 in C. elegans) ligand expressed on the 
surface of the signal-sending cell and a Notch receptor expressed on the surface of the signal-
receiving cell. There are five DSL ligands (Delta-like 1, 3 and 4, and Jagged 1 and 2) and four 
Notch receptors (Notch 1-4) in mammals. Ligand binding triggers sequential cleavages of Notch 
receptor, first by an ADAM protease at the S2 site in the juxtamembrane region of the 
extracellular domain, followed by γ-secretase at the S3 site in the transmembrane domain. The 
intracellular domain of Notch (NICD) is thus released from the membrane and translocates into 
the nucleus. Inside the nucleus, NICD forms a complex with CSL (CBF1, SuH, LAG1) DNA 
binding proteins and recruits the co-activator Mastermind to activate the target gene expression 
(Fig.1-5) (Bray, 2006; Fiuza and Arias, 2007). 
The extensively studied Notch target genes include Hes and Hey genes in mammals. They 
are related to the Hairy and Enhancer of split [E(spl)] genes in Drosophila (Fischer and Gessler, 
2003). In mouse and rat genomes, seven Hes (Hes 1-7) and three Hey (Hey 1, 2 and L) genes 
have been identified. All of these genes encode basic helix-loop-helix (bHLH) proteins. Hes1, 
Hes5, Hes7 and all members of the Hey gene family have been shown to be induced by Notch 
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(Fischer and Gessler, 2007). The Hes and Hey proteins are expressed in various tissues and have 
important functions during development and in adulthood. 
In
T
P
 additional to its canonical signaling pathway, Notch can also regulate cellular processes 
in a CSL-independent manner. It has been reported that Notch signaling inhibits myogenic 
differentiation through a CBF1-independent pathway (Shawber et al., 1996; Nofziger et al., 
1999). 
 
Regulation of Notch Signaling 
he regulation of Notch signaling is at multiple levels. Interaction of Notch with its ligands 
presented from the neighboring cells leads to trans-activation of Notch signaling. The 
extracellular cysteine-rich DSL region present in Delta and Jagged mediates the interaction with 
Notch EGF-like repeats 11 and 12 (Rebay et al., 1991; Fleming et al., 1998). The interaction 
leads to a conformational change that exposes the S2 site for cleavage by ADAM proteins. Notch 
receptor can also interact with its ligand within the same cell. This leads to cis-inhibition of 
Notch signaling by DSL ligands. It has been shown that in Xenopus, Delta-like 3 does not 
activate Notch signaling but exhibits only inhibitory effect in a cell-autonomous manner (Ladi et 
al., 2005). It has also been reported that during human keratinocyte differentiation, high level of 
Delta expression induces an inhibitory mechanism of Notch signaling (Lowell et al., 2000).  
roteolytic cleavage of Notch at the S2 site by ADAMs is a necessary step before the 
cleavage by γ-secretase and generation of NICD. Two ADAMs have been implicated in the S2 
cleavage of Notch after ligand-receptor interaction. In Drosophila, Kuzbanian mediates the 
proteolytic processing of Notch (Rooke et al., 1996; Pan and Rubin, 1997; Sotillos et al., 1997; 
Lieber et al., 2002). In mouse cells in vitro, instead of Kuzbanian ortholog ADAM10, ADAM17 
(also known as TACE) plays a prominent role in the cleavage and activation of Notch (Brou et 
al., 2000). However, ADAM10-deficient mice die at day 9.5 of embryogenesis (Hartmann et al., 
2002), which resembles the effect of mutations in Notch. ADAM17-deficient mice die between 
embryonic day 17.5 and the first day after birth (Peschon et al., 1998), which suggests that other 
proteases can cleave Notch at the S2 site in vivo. Thus, ADAM10 may play a major role in the 
S2 cleavage of Notch in vivo, with other ADAMs making tissue-specific contributions, 
corresponding to their tissue specific expressions. 
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N
otch and its ligands are glycoproteins and glycosylation plays an important role in 
regulating the ligand and receptor binding properties (Rampal et al., 2007; Stanley, 2007; Irivine, 
2008). Notch receptors and DSL ligands have conserved sequences in the EGF-like repeats that 
can be modified by O- and N- linked glycans. Only O-glycan modifications have been reported 
to be indispensible for Notch signaling. In Drosophila, the glycosyltransferase O-
fucosyltransferase-1 (OFUT1) is required for Notch activation. In addition to the O-fucose 
modification on Notch, OFUT1 is also required for the proper folding and trafficking of Notch to 
the cell surface (Okajima et al., 2008). The mammalian OFUT1, Pofut1, regulates Notch through 
its fucosyltransferase activity to achieve optimal ligand binding, but Pofut1 is not required for 
Notch cell surface expression (Stahl et al., 2008). The O-fucosylated sites can be further 
modified by Fringe, a β-1, 3-N-acetylglucosaminyltransferase. This modification is required for a 
subset of Notch-dependent events (Visan et al., 2006). 
ecent studies have shown that Notch signaling is regulated by endocytosis. A number of 
proteins associated with endocytosis, including epsin, clathrin, dynamin and auxilin, have been 
implicated indispensible for DSL ligand activity in the signal-sending cells. Structural analysis of 
the Notch heterodimer has suggested that the ADAM cleavage site (S2 site) is contained in the 
negative regulatory region (NRR) composed of three Lin12/Notch repeats and the 
heterodimerization domain (Gordon et al., 2007). Considerable force is needed to expose the S2 
cleavage site to ADAMs. Ligand endocytosis provides a good candidate to generate such force. 
Notch ectodomain undergoes trans-endocytosis and internalization by Delta-expressing cells. 
This process requires furin processing, but occurs independent of ADAM proteolysis (Nichols et 
al., 2007). Another possible mechanism explaining the requirement for ligand endocytosis is that 
trafficking into an endocytic compartment enables ligand post-translational modifications and 
makes DSL ligand competent to activate Notch after being recycled to the cell surface (Wang 
and Struhl, 2004; Le Borgne et al., 2005; Wilkin and Baron, 2005). 
 
Functions of Notch 
otch signaling contributes to the decision between two alternative cell fates. In a 
population of cells, it is characterized as “lateral inhibition”. In Drosophila, during neuroblast 
differentiation, all proneural clusters have ubiquitous but weak expression of both Delta and 
Notch. The cells that acquire a higher level of Delta differentiate into neuroblasts, while 
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activating Notch in their neighboring cells and directing them into alternative fate (Cabrera, 
1990). The small difference within the roughly equivalent population of cells is thus amplified 
by Delta-Notch signaling. In mammals, it has been shown that lateral inhibition plays an 
important role during hair cell development in the inner ear (Kiernan et al., 2005). When it 
comes to the cell fate decision between two sister cells, Notch is associated with “asymmetric 
cell division”. Asymmetric division of stem cells gives rise to one stem cell and one committed 
daughter cell, which is regulated by stem cell niche. It has been reported that upon apical-basal 
oriented cell divisions, a high level of Delta-like 1 expression is present in committed daughter 
cells that maintain contact with the plasmalemma, with a low level of Delta-like 1 expression in 
stem cells, suggesting the involvement of Notch signaling in oriented asymmetric cell division 
(Kuang et al., 2007). It has also been shown that Numb, a well-known Notch negative regulator, 
is distributed asymmetrically during satellite cell division (Conboy and Rando, 2002). 
D
N
efects in Notch signaling are involved in several human diseases. Mutations in Notch 1 
and Notch 3 cause an autosomal vascular disorder resulting in the loss of the arteriolar vascular 
smooth muscle cells (Gridley, 2003; Harper et al., 2003). Mutations involving either the Notch 
heterodimerization domain or the PEST domain give rise to T-cell acute lymphoblastic leukemia 
(Weng et al., 2004). Mutations in Dll3 result in rib defects, causing abonormalities in vertebral 
segmentation and trunk size (Girdley, 2003). Mutations in Jagged 1 cause Alagille syndrome, 
characterized by kidney, eye, heart and skeleton developmental problems and defects in bile duct 
formation that leads to liver problems (Li et al., 1997; Oda et al., 1997). 
 
Notch Signaling in Myogenesis 
otch signaling plays an important role in the development of myogenic lineage 
(Vasyutina et al., 2007a). Notch signaling is activated during satellite cell activation and 
proliferation (Conboy and Rando, 2002). Increased Notch signaling inhibits myogenic 
differentiation. Ectopic expression of NICD attenuates myogenic differentiation by down-
regulating MyoD (Kopan et al. 1994; Conboy and Rando, 2002). It has also been reported that 
high levels of Dll1 suppress myogenic differentiation of cultured C2C12 cells by down-
regulation of MyoD (Kuroda et al., 1999). A CBF1-independent inhibition of myogenic 
differentiation has been proposed in C2C12 myogenic cells, where the activity of MyoD is not 
affected but the expression of myogenin is down-regulated (Shawber et al., 1996; Nofziger et al., 
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1999). Decreased Notch signaling promotes myogenic differentiation. Over-expression of Notch 
antagonist, Numb, up-regulates the expression of muscle differentiation genes (Conboy and 
Rando, 2002; Kitzmann et al., 2006). Inhibition of Notch signaling by using a pharmacological 
γ-secretase inhibitor (DAPT) enhances differentiation of murine and human myoblasts 
(Kitzmann et al., 2006). Studies utilizing conditional RBP-J mutant mice and hypomorph Dll1 
mutant mice shed lights on the role of Notch signaling in maintaining the myogenic progenitor 
population in skeletal muscle (Schuster-Gossler et al., 2007; Vasyutina et al., 2007b). Both the 
conditional RBP-J and the hypomorph Dll1 mutations result in premature myogenic 
differentiation, leading to a depletion of the progenitor pool. This results in lack of muscle 
growth and severe muscle hypotrophy. Thus, Notch signaling is required for preventing 
uncontrolled differentiation and maintaining the progenitor population during muscle 
development. However, the mechanism responsible for regulation of Notch activity in myogenic 
cells is not fully understood. 
 
Delta-like 1 
D
S
elta-like 1 (Dll1) is one of the canonical DSL ligands that interact with Notch receptors. 
Like Notch receptors, Dll1 is also a type I transmembrane protein. Mouse Dll1 contains a DSL 
domain and nine EGF-like repeats in its extracellular domain (Fig.1-5, left panel). The DSL 
domain together with the flanking N-terminal domain and the first two EGF-like repeats are 
responsible for the interaction with Notch receptors (Parks et al., 2006). After the transmembrane 
domain, the intracellular region of Dll1 contains multiple lysine residues and a C-terminal PDZ 
(PSD-95/Dlg/ZO-1) binding motif (Pintar et al., 2007). 
imilar to the sequential proteolysis of Notch, Dll1 also undergoes regulated 
intramembrane proteolysis (RIP) in the juxtamembrane and transmembrane regions by ADAMs 
and γ-secretase, respectively. The cleavage by ADAMs generates a transmembrane and 
intracellular domain (TMIC) of Dll1 and an extracellular fragment (EC), which is released to the 
medium (Six et al., 2003; Dyczynska et al., 2007). ADAM10 was implicated in processing of 
mouse (Six et al., 2003) and rat Dll1 (LaVoie et al., 2003). The extent of Dll1 cleavage is 
reduced to ~50% in ADAM10-/- mouse embryonic fibroblasts (MEFs) compared to wild-type 
MEFs (Six et al., 2003), which indicates that other ADAMs may be capable to cleave Dll1 in 
ADAM10-/- cells. 
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D
ll1 plays an essential role in regulating the canonical Notch signaling pathway. Dll1 can 
affect Notch signaling through cell-cell interaction in trans, and in a cell-autonomous manner in 
cis. Interaction between Dll1 and Notch receptor in the neighboring cell leads to sequential 
proteolytic cleavages and activation of Notch. Interaction between Dll1 and Notch within the 
same cell inhibits Notch signaling (Sakamoto et al., 2002; D’Souza et al., 2008). ADAM 
proteolysis of Dll1 has presumably dual effects on Notch signaling. ADAM proteolysis in the 
signal-sending cell would limit the ligand availability and down regulate Notch activity. RECK 
(reversion-inducing cysteine-rich protein with Kazal motifs) is a physiological inhibitor of 
ADAM10. In RECK-/- mice, Notch signaling is down-regulated because of excessive Dll1 
shedding by ADAM10, which results in defective neurogenesis (Muraguchi et al., 2007). In 
cultured mammalian cells, soluble extracellular domain of Dll1 inhibits Notch activity 
(Trifonova et al., 2004). In addition to inhibition of Notch trans-activation, ADAM proteolysis 
of Dll1 may activate Notch signaling in a cell-autonomous manner by relief of cis-inhibition 
(Dyczynska et al., 2007; Zolkiewska, 2008). 
fter cleavage by ADAMs, the membrane-tethered Dll1 transmembrane and intracellular 
domain (TMIC) undergoes further proteolysis by γ-secretase (Ikeuchi and Sisodia, 2003; LaVoie 
and Selkoe, 2003; Six et al., 2003). The product of γ-secretase cleavage is the intracellular 
fragment (IC) of Dll1, which contains a typical RKRP sequence targeting it to the nucleus. 
Marked transcriptional stimulation of Gal4-luciferase reporter has been observed with co-
transfection of Delta1-Gal4VP16 chimera. The transactivation is inhibited upon treatment with γ-
secretase inhibitor (Ikeuchi and Sisodia, 2003). Dll1 IC has been reported to enhance 
transforming growth factor-β (TGF-β) induced transcriptional activity of Smad3 (Hiratochi et al., 
2007).  
ll1 also mediates cellular processes through its C-terminal PDZ (PSD-95/Dlg/ZO-1) 
binding motif. Dll1 interacts with Activin receptor interacting protein 1 (Acvrinp1) (Pfister et al., 
2003), disc large homolog 1 (Dlg1) (Six et al., 2004) and membrane-associated guanylate kinase 
with inverted domain arrangement 1 (MAGI1) (Mizuhara et al., 2005). It has been shown that 
PDZ interactions are dispensable for activation of Notch signaling. In fact, Delta with a mutated 
PDZ binding motif has enhanced signaling potential (Estrach et al., 2007). 
 
ADAMs 
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ADAMs are type I transmembrane proteins that contain a metalloprotease and a 
disintegrin-like domain. ADAM stands for “A Disintegrin And Metalloprotease”. Together with 
snake venom metalloproteases (SVMPs) and ADAMs containing thrombospondin repeats 
(ADAMTS proteins), ADAM proteins belong to the adamalysin family of the metzincin 
subgroup of zinc proteases. The matrix metalloproteases (MMPs) also belong to the metzincin 
subgroup. To date, 23 ADAMs have been identified in the human genome. Analysis of their 
structures shows that all ADAM proteins contain N-terminal signal peptide, pro-domain, 
metalloprotease, disintegrin, cysteine-rich, epidermal growth factor (EGF)-like, transmembrane 
and cytoplasmic domains. Structural analysis revealed that the active site in the metalloprotease 
domain contains zinc and water atoms that are necessary for hydrolysis of ADAM substrates. 
The zinc binding consensus sequence is HEXXHXXGXXH. The zinc ion is coordinated by three 
conserved histidine residues and a downstream methionine (Stocker et al., 1995). ADAMs are 
involved in various biological events, including membrane protein shedding and proteolysis, cell 
adhesion and cell migration. They play important roles in development and diseases, such as 
cancer, asthma and Alzheimer’s disease (Blobel, 2002; Seals and Courtneidge, 2003; Arribas et 
al., 2006). 
A
A
DAM proteins have important functions in regulation of Notch signaling because of their 
involvement in the proteolytic processing of both Notch receptors and DSL ligands. As 
previously described, two ADAMs, ADAM10 and ADAM17 have been implicated in the S2 
cleavage of Notch. ADAM10 is also known to process Dll1, with potential contributions from 
other ADAMs. In addition to the cleavage of Dll1, mammalian Jagged 1 and Jagged 2 have been 
observed to be processed at the juxtamembrane region. In CHO cells, transfected Jagged 1 has 
been shown to be cleaved by ADAM17 (Ikeuchi et al., 2003; LaVoie et al., 2003). 
 
ADAM12 
DAM12 is an active metalloprotease associated with development and regeneration of 
skeletal muscle (Yagami-Hiromasa et al., 1995; Gilpin et al., 1998; Engvall and Wewer, 2003). 
There are two splice variants existing in human, ADAM12-L and ADAM12-S. ADAM12-L is a 
transmembrane protein with a prototypical ADAM structure. ADAM12-S is a soluble protein 
where the transmembrane and cytoplasmic domains are replaced by 33 amino acids in the C-
terminus (Fig.1-6). ADAM12 is synthesized in the rough endoplasmic reticulum and is modified 
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in the Golgi apparatus. Processing of the pro-domain takes place in trans-Golgi network by a 
furin-like pro-protein convertase. Cys179 in the pro-domain coordinates the active site zinc ion 
and keeps ADAM12 inactive by a cysteine-switch mechanism (Loechel et al., 1999; Cao et al., 
2002). ADAM12 becomes an active metalloprotease after being delivered to the extracellular 
space (Loechel et al., 1998; Loechel et al., 1999). 
P
A
D
T
hysiological ADAM12 substrates include insulin-like growth factor binding proteins 
(IGFBP)-3 and IGFBP-5 (Loechel et al., 2000; Shi et al., 2000), epidermal growth factor 
receptor (EGFR) ligands (Asakura et al., 2002; Kurisaki et al., 2003), placental leucine 
aminopeptidase (P-LAP) (Ito et al., 2004) and Delta-like 1 (Dyczynska et al., 2007). These 
proteolytic events regulate diverse cellular responses, including cell proliferation, differentiation, 
migration and invasion (Kveiborg et al., 2008). 
pproximately 30% of ADAM12-deficient mice die before weaning (Kurisaki et al., 
2003). Most muscles in the ADAM12-deficient mice appear normal, with some impaired 
formations of the neck and shoulder muscles. In some deficient mice, the interscapular brown 
adipose tissue is reduced. These findings suggest that ADAM12 may be involved in myogenesis 
and adipogenesis (Kurisaki et al., 2003; Masaki et al., 2005; Kveiborg et al., 2008). 
uring mouse embryogenesis, ADAM12 is expressed primarily in mesenchymal tissues 
that give rise to muscle and bone (Kurisaki et al., 1998). ADAM12 mRNA is not detected in 
adult muscle tissue in mice, but its transcription is up-regulated during muscle regeneration 
(Borneman et al., 2000; Galliano et al., 2000). During differentiation of C2C12 myogenic cells, 
ADAM12 expression is down-regulated in differentiated myotubes, whereas in a pool of 
quiescent reserve cells, ADAM12 expression is maintained, suggesting the role of ADAM12 in 
determination of reserve cells (Cao et al., 2003). 
he expression of ADAM12 is markedly up-regulated in cancer of the breast, prostate, 
liver, lung, stomach, colon, bladder, brain and bone (Kveiborg et al., 2008). ADAM12 is also 
expressed by several tumor cell lines, including a rhabdomyosarcoma cell line (Gilpin et al., 
1998). Recent studies using transgenic mouse models suggest that ADAM12 promotes tumor 
progression. In mice spontaneously developing breast cancer due to polyoma middle T antigen 
expression, forced expression of ADAM12 increased the tumor progression (Kveiborg et al., 
2005), whereas in a mouse model for prostate cancer, knocking-out ADAM12 led to reduced 
tumor development (Peduto et al., 2006). ADAM12 has been identified as one of the candidate 
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cancer genes associated with human breast cancer in a large scale cancer mutation discovery and 
screen (Sjoblom et al., 2006). Three missense mutations in ADAM12 were identified, including 
a highly conserved aspartic acid in the metalloprotease domain changed to a histidine, a highly 
conserved glycine in the disintegrin domain changed to a glutamic acid, and a leucine in the 
cytoplasmic tail changed to a phenylalanine. The first two mutations of highly conserved 
residues have been shown to interfere with the intracellular trafficking of ADAM12 and result in 
loss of function ADAM12 at the cell surface (Dyczynska et al., 2008). 
 
Goal of Study 
M
T
uscle satellite cells are commonly identified by the expression of Pax7. Pax7 is essential 
in protecting satellite cells from apoptosis (Relaix et al., 2006). However, the mechanism for 
Pax7-mediated satellite cell survival is not clear. When quiescent Pax7-expressing satellite cells 
are activated, they co-express Pax7 and MyoD. During proliferation, most of the cells down 
regulate Pax7 and differentiate, while others maintain Pax7 but lose MyoD and return to 
quiescence (Zammit et al., 2004). Notch signaling plays a critical role during this process in 
preventing myogenic differentiation and maintaining the satellite cell pool. The regulations of 
Notch activity in myogenic cells are not well understood. In alveolar rhabdomyosarcoma, Pax7 
is involved in a specific chromosomal translocation. The generation of oncogenic fusion proteins 
Pax3-FKHR or Pax7-FKHR leads to decreased expression of Pax7 (Tiffin et al., 2003; Tomescu 
et al., 2004). The process of wild-type Pax7 protein down-regulation is yet to be fully 
investigated. 
he goal of this dissertation was to gain a better understanding in these fundamental 
questions in myogenic differentiation and in rhabdomyosarcoma, with emphasis on the following 
aspects: the cleavage of Notch ligand, Dll1 by ADAM metalloproteases and the impact of Dll1 
cleavage on Notch signaling and on muscle satellite cell self-renewal and differentiation; the 
involvement of other mediating factors in Pax7 anti-apoptotic function and in satellite cell 
survival; and the molecular mechanism of inhibition of Pax7 by the fusion protein generated in 
rhabdomyosarcoma. 
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Adapted with permission from © Zammit et al., 2004. Originally published in The Journal of 
Cell Biology. doi:10.1083/jcb.200312007 
Figure 1-1. Model of satellite cell self-renewal. Quiescent satellite cells express Pax7 (Green). 
During muscle regeneration, quiescent satellite cells are activated and proliferate. Proliferating 
satellite cells co-express Pax7 and MyoD (green and red tartan). During satellite cell 
proliferation, most of cells down-regulate Pax7, maintain MyoD (red), and differentiate to 
produce myofibers (red pathway). Other cells down-regulate MyoD expression while 
maintaining Pax7 (green), and renew the satellite cell pool (green pathway). Signaling between 
the myofiber and the quiescent and proliferating satellite cells (orange arrows) and signaling 
between the cells within the clusters (blue arrow) are essential for divergent satellite cell fate 
determination. 
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Figure 1-2. Pax protein family. Pax proteins are divided into four groups based on their 
structures. The paired domain (red) characterizes the family and is present in all Pax proteins. 
Members of group I, II and III have an octapeptide (yellow). Members of group II contain a 
partial one helixed homeodomain (blue), while members of group III and IV contain a three 
helixed homeodomain (blue). Pax3 and Pax7 belong to group III of the Pax protein family. 
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Figure 1-3. Chromosomal translocations and generation of fusion proteins. (A) Diagram of 
chromosomal translocations between chromosome 1 or 2 and chromosome 13 (Adapted with 
permission from © Barr, 2001. Originally published in Oncogene. 20: 5736-5746). (B) 
Comparison of the fusion products to the associated wild-type proteins. The DNA binding 
domains (DBD) of Pax proteins are connected with the transactivation domain (TAD) of the 
FKHR protein. 
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Figure 1-4. Domains found in the Notch receptor and its ligand Delta. The extracellular 
region of the Notch receptor includes EGF-like repeats (yellow), Lin-12 repeats (green) and 
heterodimerization domains (navy). The intracellular part of Notch contains RAM region (blue), 
Ankyrin repeats (orange), a transactivation domain (purple) and a PEST domain (pink) (right 
panel). Notch ligand Delta-like 1 contains a DSL domain (red) and nine EGF-like repeats 
(yellow) in its extracellular region (left panel). 
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Figure 1-5. Canonical Notch signaling pathway. Binding of Delta ligand (pink) to the Notch 
receptor (purple) elicits sequential proteolytic cleavages of Notch receptor, first at the S2 site by 
ADAM metalloproteases (ADAM10 or ADAM17) (blue), followed with cleavage at S3 site by 
γ-secretase (brown). The Notch intracellular domain (NICD) is released and translocates into the 
nucleus. In the nucleus, NICD interacts with CSL DNA binding proteins (orange), recruits the 
co-activator Mastermind (green) and leads to the target gene expression. 
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Figure 1-6. Structures of human ADAM12-L and ADAM12-S. Human ADAM12 exists in 
two forms as a result of alternative splicing. ADAM12-L is a transmembrane protein with a 
prototypical ADAM structure consisting of the N-terminal signal peptide (pink), pro-domain 
(purple), metalloprotease domain (navy), disintegrin domain (blue), cysteine-rich domain (light 
blue), EGF-like domain (green), transmembrane domain (yellow) and cytoplasmic tail (brown). 
ADAM12-S is a soluble protein with a short 33-amino acid C-terminus (orange). 
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Introduction 
N
S
F
otch signaling regulates cell fate decisions during development and in the adult (Lai, 
2004; Kadesch, 2004; Louvi and Artavanis-Tsakonas, 2006). The signaling pathway is activated 
by direct interactions between Notch receptor, a transmembrane protein present at the surface of 
a signal-receiving cell, and a DSL (Delta/Serrate/Lag2) ligand, a transmembrane protein at the 
surface of a signal-sending cell. In mammals, there are four different Notch receptors (Notch 1–
4), and five DSL ligands (Delta-like 1, 3, and 4 and Jagged 1 and 2). Ligand-bound Notch 
undergoes proteolytic cleavage at the S2 site in the extracellular domain, which is mediated by 
ADAM10 or ADAM17 (Brou et al., 2000; Mumm et al., 2000; Hartmann et al., 2002), members 
the ADAM family of metalloprotease-disintegrins (Blobel, 2005; Huovila et al., 2005). This is 
followed by the cleavage at the S3 site in the transmembrane domain of Notch by a γ-secretase 
complex (Mumm and Kopan, 2000; Selkoe and Kopan, 2003). The intracellular domain of Notch 
translocates to the nucleus, where it interacts with CSL (CBF1, Su(H), Lag-1) transcription 
factors and activates expression of target genes (Hayward, 2004). 
imilar to their receptors, Notch ligands also undergo ADAM-mediated cleavage in their 
extracellular domains, which is then followed by processing by γ-secretase (Ikeuchi and Sisodia, 
2003; Six et al., 2003; LaVoie and Selkoe, 2003; Bland et al., 2003). Two ADAMs were 
postulated to cleave Notch ligands in mammalian cells, ADAM10 and -17. ADAM10 was 
implicated in the processing of mouse (Six et al., 2003) and rat Delta-like 1 (Dll1) (LaVoie and 
Selkoe, 2003), whereas ADAM17 was suggested to cleave rat Jagged 1 (LaVoie and Selkoe, 
2003). Proteolytic cleavage of Dll1 in ADAM10-/- mouse embryonic fibroblasts (MEFs) still 
amounts to 50% of the processing observed in ADAM10+/+ MEFs (Six et al., 2003), suggesting 
that ADAM10 is only partially responsible for Dll1 cleavage and other ADAMs may account for 
the remaining processing in ADAM10-/- cells. MEFs express several ADAM proteins with 
catalytically active metalloprotease domains, including ADAM9, -12, -15, and -17 (Sahin et al., 
2004). However, to date, none of these ADAMs has been shown to be capable of cleaving Dll1. 
urthermore, although it is well established that proteolytic processing of Notch ligands 
down-regulates Notch signaling in neighboring cells (Qi et al., 1999; Mishra-Gorur et al., 2002), 
the effect of ligand cleavage on the Notch pathway within the same cell is less clear. Notch 
receptors can associate with their ligands in a cell-autonomous manner (Sakamoto et al., 2002; 
Katsube and Sakamoto, 2005; Ladi et al., 2005). Associations between receptors and ligands in 
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cis decrease Notch receptivity and attenuate the Notch pathway (Sakamoto et al., 2002; Katsube 
and Sakamoto, 2005; Ladi et al., 2005; Franklin et al., 1999). In Drosophila, proteolytic 
processing of Delta by ADAM10-like (Kuzbanian-like) alleviates the inhibitory effect of Delta 
on Notch in the same cell (Sapir et al., 2005). In contrast, processing of Jagged 1 in mammalian 
cells by ADAM17 was postulated to inhibit Notch signaling in cis due to competition of the C-
terminal fragments of Jagged 1 and Notch for γ-secretase (LaVoie and Selkoe, 2003). 
In
W
H
 this study, we have tested the ability of several ADAMs other than ADAM10 to cleave 
murine Dll1 and examined the effect of Dll1 cleavage on Notch signaling in the same cell. We 
show that ADAM12 can efficiently process Dll1 but not Notch1. Dll1 cleavage by ADAM12 
activates Notch in a cell-autonomous manner. In addition, we show that two other ADAMs, 
ADAM9 and -17, but not ADAM15, are capable of Dll1 processing. ADAM9 and -17 are also 
capable to activate Notch in a cell-autonomous manner. The extent of processing of Dll1 
transfected into ADAM9/12/15-/- MEFs is reduced when compared with the processing in wild 
type MEFs, suggesting that the endogenous ADAM9 and/or ADAM12 present in wild type 
MEFs contribute to Dll1 cleavage. 
 
Results 
e demonstrated that the full length Dll1 (FL Dll1, ~90kDa) was cleaved by ADAM12. 
The C-terminal Dll1 fragment (CTF Dll1, ~29kDa) was then cleaved by γ-secretase. The soluble 
N-terminal fragment of Dll1 (NTF Dll1, ~60kDa) was released to culture medium (Fig.2-1). The 
catalytically inactive mutant form of ADAM12, E349Q, did not process Dll1. ADAM12-
catalyzed processing of Dll1 was more efficient at high cell density and occurred in cis. In 
addition, ADAM12 lacked α-secretase activity toward Notch1. 
aving established that Dll1, a Notch ligand but not Notch itself, is cleaved by ADAM12, 
we examined the effect of Dll1 cleavage on Notch signaling. To monitor the activation status of 
the Notch pathway, we utilized CBF1-luc reporters containing four (Hsieh et al., 1996) or eight 
binding sites (Peng et al., 2000) for CBF1, a CSL transcription factor activated by Notch 
(Hayward, 2004). NIH3T3 cells were transiently co-transfected with mouse Notch1 and a Notch 
reporter and co-cultured with CHO cells stably transfected with Dll1 (CHO.Dll1) or with empty 
vector (CHO.Vec). Co-culture with CHO.Dll1 cells led to higher activity of the reporter than co-
culture with CHO.Vec cells (Fig.2-2A), suggesting that the exogenous Dll1 expressed in 
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CHO.Dll1 cells activated Notch. The extent of this activation was more modest than reported 
previously in several other studies, in which quail QT6 or mouse L fibroblasts were employed to 
present Notch ligands to Notch-expressing cells (Ladi et al., 2005; Jarriault et al., 1998). One of 
the reasons of a modest increase in Notch activity in our system may be that co-culture with 
control CHO.Vec cells had already stimulated Notch 4-5-fold when compared with the 
conditions without CHO.Vec cells (results are not shown). This was most likely due to high 
expression levels of the endogenous Notch ligands in CHO cells that were capable of Notch 
activation. In such case, further increase of the amount of ligand by transfecting exogenous Dll1 
might have had a limited effect and, understandably, might not have produced additional strong 
increase in Notch activity. Nonetheless, increased activity of the Notch reporter induced by co-
culture with CHO.Dll1 versus CHO.Vec cells was observed for the reporter containing intact, but 
not mutated, CBF1 binding sites (Fig.2-2A), which validated our co-culture assay to measure 
Notch activation. When Dll1 was further co-expressed with Notch in NIH3T3 cells, the 
activation of Notch was abolished (Fig.2-2B) due to formation of Notch/Dll1 complexes in cis 
(Sakamoto et al., 2002; Katsube and Sakamoto, 2005; Ladi et al., 2005; Franklin et al., 1999). 
Most importantly, further co-transfection of Dll1-processing ADAM12 resulted in re-activation 
of the Notch reporter (Fig.2-2B). The catalytically inactive mutant of ADAM12, E349Q, which 
did not process Dll1, did not activate Notch either (Fig.2-2B). This result suggested that when 
Notch and Dll1 were expressed in the same cell, proteolytic processing of Dll1 increased the 
ability of Notch to receive signals and to activate its downstream signaling pathway. 
W
T
e next examined the abilities of three other ADAMs, ADAM9, -15 and -17 to cleave 
Dll1. All ADAMs used in this study form stable complexes with Dll1. Co-transfection with Dll1 
demonstrated that ADAM9 and -17, similarly to ADAM12, had catalytic activity toward Dll1, 
but ADAM15 was not able to process Dll1. 
o test the effect of Dll1 cleavage by different ADAM proteins on Notch signaling, 
NIH3T3 cells were transiently co-transfected with mouse Notch1, CBF1-luc reporter containing 
eight CSL binding sites, and one of the ADAM constructs or empty vector. Notch signaling was 
similar in cells co-transfected with empty vector and with ADAM9, -12, -15 or -17 when 
NIH3T3 cells were co-cultured with CHO.Vec cells. Co-culture with CHO.Dll1 cells increased 
Notch reporter activity to a similar extent in all cases as a result of trans-activation. When 
NIH3T3 cells were further co-transfected with Dll1, Dll1 inhibited Notch signaling in cis in 
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vector-transfected cells. Most importantly, in cells co-transfected with ADAM9, -12 and -17, cis-
inhibition of Notch activity by Dll1 in the same cell was relieved due to the efficient cleavage of 
Dll1 by these ADAM proteases. In ADAM15 co-transfected NIH3T3 cells, no relief of cis-
inhibition was observed (Fig.2-3). This result indicated that proteolytic processing of Dll1 by 
ADAM9, -12 and -17 increased Notch signaling in a cell-autonomous manner. 
T
A
M
o determine whether ADAM proteases studied in this work can process Dll1 when they 
are expressed at the endogenous levels, we compared the amount of Dll1 cleavage in wild type 
(wt) and ADAM9/12/15-/- triple knock-out (T) MEFs. Dll1 was transfected into wt-MEFs or T-
MEFs, and the extent of Dll1 cleavage was examined by subjecting total cell lysates to 
immunoblotting with anti-Dll1 antibody (Fig.2-4A) or by immunoprecipitation of FL Dll1 and 
CTF Dll1 from 35S-labeled cells (Fig.2-4B). Significant differences in the intensities of the bands 
corresponding to FL Dll1 and CTF Dll1 in Fig.2-4A precluded an accurate quantification of the 
extent of cleavage (the CTF Dll1/FL Dll1 ratio). These differences were even more pronounced 
in Fig.2-4B because the number of cysteine and methionine residues in FL Dll1 is ~10 higher 
than in CTF Dll1 (Six et al., 2003). Nevertheless, whereas the amounts of FL Dll1 in wt-MEFs 
and T-MEFs were similar, the level of CTF Dll1 in T-MEFs corresponded to ~60% of the level 
in wt-MEFs (Fig.2-4AB). Because ADAM15 is not capable of cleaving Dll1, this result 
suggested that ADAM9 and/or ADAM12 contributed to Dll1 processing in wt-MEFs. 
t the end, we showed that the endogenous Dll1 was subject to proteolytic processing in 
confluent, differentiating myoblast cultures, giving rise to the 29-kDa fragment, and that the 
endogenous ADAM12 contributed to this processing. 
 
Discussion 
ammalian Dll1 expressed in HEK293, COS, CHO, N2a, or NIH3T3 cells was cleaved by 
endogenous ADAMs present in these cells (Ikeuchi and Sisodia, 2003; Six et al., 2003; LaVoie 
and Selkoe, 2003). Transfection of Dll1 into ADAM10-/- or ADAM10+/+ MEFs demonstrated 
that the cleavage was reduced by ~50% in the absence of ADAM10 (Six et al., 2003). This result 
suggested that ADAM10 was only partially responsible for Dll1 cleavage and that other ADAMs 
catalyzed the remaining cleavage of Dll1 in ADAM10-/- cells. MEFs express several 
catalytically active ADAMs, including ADAM9, -12, -15, and -17 (Sahin et al., 2004), and we 
focused our study on these proteases. Here we show that ADAM9, -12, and -17, but not 
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ADAM15 are capable of Dll1 cleavage. Furthermore, processing of Dll1 transfected into 
ADAM9/12/15-/- MEFs was diminished when compared with processing in wild type MEFs 
(Fig.2-4). This result suggested that Dll1 was also subject to processing by the endogenous 
ADAM9 or ADAM12 or both (since ADAM15 was not capable of cleaving Dll1 even when 
over-expressed in COS-7 cells, most likely it did not contribute to Dll1 processing in MEFs at 
the endogenous level). Although the reduction of Dll1 cleavage in ADAM9/12/15-/- MEFs was 
rather modest (~40%), it was consistent with ~50% inhibition of Dll1 processing observed in 
ADAM10-/- MEFs (Six et al., 2003) and with the remaining activity of ADAM17, which might 
have also contributed to the processing. 
The ability of ADAM9, -12 and -17 to cleave Dll1 allowed us to study the effect of ligand 
cleavage on Notch signaling. Although shedding of the extracellular domain of Notch ligand 
limits the ligand presentation in trans and terminates Notch signaling in a neighboring cell (Qi et 
al., 1999; Mishra-Gorur et al., 2002), cell-autonomous effects of ligand cleavage are less clear. 
Notch ligands form complexes in cis with Notch, which leads to sequestration of Notch 
receptors, reduction of Notch receptivity to signals from outside, and attenuation of Notch 
signaling (Sakamoto et al., 2002; Katsube and Sakamoto, 2005; Ladi et al., 2005; Franklin et al., 
1999). Shedding of the extracellular domain of the ligand could relieve this inhibitory effect and 
activate Notch, a scenario that is supported by results of in vivo experiments in flies. Over-
expression of Kuzbanian-like in juxta-marginal cells in Drosophila wing discs (which are 
characterized by high levels of Delta and low levels of Notch signaling) resulted in increased 
expression of Notch target genes (Sapir et al., 2005). Alternatively, the C-terminal fragment of a 
ligand could compete with Notch S2 cleavage product for γ-secretase and, thus, interfere with 
Notch signaling. Indeed, over-expression of an ectodomain-truncated Jagged 1 in COS-7 cells 
together with an ectomain-truncated Notch led to inhibition of the Notch function (LaVoie and 
Selkoe, 2003). However, expression of a truncated Jagged that mimicked an already cleaved 
Jagged, did not allow evaluation of the actual effect of the removal of the N-terminal portion of 
Jagged by ADAMs. In our studies, both Dll1 and Notch constructs represented the intact 
proteins, and the relative contribution of Dll1 ectodomain shedding (a stimulatory effect) and 
competition of Dll1 and Notch C-terminal fragments for γ-secretase (an inhibitory effect) were 
addressed. Our results demonstrate that ADAM12, capable of mediating a constitutive cleavage 
of Dll1 but not of Notch, activated Notch signaling in a cell autonomous manner, whereas the 
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catalytically inactive ADAM12 mutant did not process Dll1 and did not activate Notch (Fig.2-
2B). Furthermore, Dll1-processing by ADAM9 and -17 increased the ability of Notch to activate 
its downstream signaling, while ADAM15, unable to cleavage Dll1, was unable to activate 
Notch (Fig.2-3). Thus, alleviation of the inhibition of Notch mediated by Dll1 appears to 
outweigh the generation of a Dll1 fragment that can compete for γ-secretase. 
T
M
he essence of Notch signaling is the amplification of small differences in the levels of 
Notch receptors and their ligands between adjacent cells (Lai, 2004; Kadesch, 2004; Louvi and 
Artavanis-Tsakonas, 2006). Cells that are initially equivalent but at one point develop a bias 
toward receptors or ligands will eventually become signal-receiving and signal-sending cells, 
respectively. Amplification of the differences in receptor/ligand levels is mainly achieved by a 
transcriptional feedback mechanism (Lai, 2004; Kadesch, 2004; Louvi and Artavanis-Tsakonas, 
2006). We propose that proteolytic cleavage of Dll1 may represent another mechanism for 
reinforcing small differences in the signaling capacities of different cells and for establishing the 
uni-directionality in Notch signaling. 
 
Materials and Methods 
Expression constructs 
ouse Dll1 cDNA was amplified by PCR using a full-length clone (ID 6402691; 
Invitrogen) as a template and cloned into pIRESpuro expression vector. c-Myc-Dll1 containing 
an internal c-Myc tag between amino acids 46 and 47, inserted into the SacII site in Dll1 cDNA, 
was cloned into pcDNA3.1 vector. Mouse full-length cDNAs of ADAM9, -12, -15, and -17 were 
cloned into pcDNA3.1 vector; these ADAMs contained c-Myc and His6 tags at their termini. 
The E349Q was generated by site-directed mutagenesis using QuikChange kit (Stratagene). 
Mouse Notch1 containing an intact extracellular domain and in which 348 C-terminal amino 
acids were replaced with 6 copies of c-Myc tag (pCS2+mN1FL6MT) was provided by R. Kopan 
(Washington University). CBF1 reporters containing four wild type or mutated CBF1 binding 
sites (pJH23A and pJH25A, respectively) were provided by D. Hayward (Johns Hopkins School 
of Medicine); Notch reporter containing eight CBF1 binding sites (pJT123A) was provided by P. 
D. Ling (Baylor College of Medicine). 
 
Cells 
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B
C
IH3T3 and CHO-K1 cells were obtained from American Tissue Culture Collection. 
NIH3T3 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM), supplemented 
with 10% fetal bovine serum, at 37 °C in the presence of 5% CO2 under a humidified 
atmosphere. CHO-K1 cells were grown in F12K nutrient mixture, supplemented with 10% fetal 
bovine serum, at 37 °C in the presence of 5% CO2 under a humidified atmosphere. MEFs 
isolated from ADAM9/12/15-/- (Sahin et al., 2004) or from wild type mice and immortalized 
with simian virus 40 large T antigen were grown on gelatin-coated dishes in DMEM containing 
10% FCS and 100 µg/ml each penicillin and streptomycin. 
 
Plasmid transfection 
ne day after plating, cells were transfected using Fugene6 (Roche Applied Science). In 
experiments with MEFs, the amount of total DNA was 1 µg/well in a 6-well plate; for CBF1 
reporter assays, 2.05 µg of DNA/well was used (see below). For stable expression of c-Myc-Dll1 
in CHO-K1 cells, transfected cells were grown for 2 weeks in the presence of Geneticin (800 
µg/ml); a clone positive for c-Myc-Dll1 expression was isolated. Cells with the highest 
expression of cell-surface c-Myc were further selected by cell sorting using FACS Calibur (BD 
Biosciences). 
 
Cell treatments 
efore harvesting, MEFs were incubated with 1 µM L685,458 (a γ-secretase inhibitor) for 
6 h. 
 
Western blotting 
ellular proteins were extracted with extraction buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-
sulfonyl fluoride hydrochloride (AEBSF), 5 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml 
pepstatin A, 10 mM 1,10-phenanthroline; 0.5 ml extraction buffer/well in a 6-well plate). Cell 
extracts were centrifuged at 21,000 x g for 15 min, and supernatants were resolved by SDS-
PAGE and transferred to a nitrocellulose membrane. The membrane was blocked with 3% (w/v) 
dry milk and 0.3% (v/v) Tween 20 in DPBS, then incubated with primary antibody in blocking 
buffer, followed by incubation with horseradish peroxidase-labeled secondary antibody and 
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detection using the WestPico chemiluminescence kit (Pierce). Primary antibody rabbit anti-Dll1 
(Santa Cruz Biotechnology, H-265; 0.2 µg/ml) was used. Secondary antibody was horseradish 
peroxidase (HRP)-conjugated anti-rabbit IgG. Intensities of the bands in Western blots were 
determined by densitometry and quantified using ScionImage software. Each experiment 
involving quantitative determination of Dll1 cleavage was repeated at least three times. 
 
Metabolic labeling and immunoprecipitation 
2
N
4 h after transfection with c-Myc-Dll1, MEFs were transferred to 
DMEM:methionine/cysteine-free DMEM (1:9) containing 35S-labeled EasyTag Express protein 
labeling mix (267 µCi/ml, PerkinElmer Life Sciences). After 16 h, cell extract was collected, cell 
debris was removed by centrifugation, and supernatant was used for immunoprecipitation with 
anti-Dll1 antibody (H-265, 5 µg/ml). After pre-clearing, supernatants were incubated with 
antibodies and protein G-Sepharose 4 Fast Flow (Amersham Biosciences), the beads were 
washed three times with extraction buffer, and immuno-complexes were eluted with SDS-PAGE 
sample buffer and analyzed by electrophoresis and autoradiography. 
 
CBF1 reporter assay 
IH3T3 cells in 6-well plates were transfected at 50% confluence with 0.5 µg of Notch1, 
0.5 µg of CBF1 firefly luciferase reporter, 0.05 µg of Renilla luciferase (pRL-TK), 0.5 µg of 
ADAM12, ADAM12 E349Q, ADAM9, ADAM15, ADAM17 or empty pcDNA3.1 vector, and 
0.5 µg of Dll1 or empty pIRES-puro vector. Twenty-four hours after transfection, CHO-K1 cells 
stably transfected with c-Myc-Dll1 or with empty vector were added (106 cells/well) and co-
cultured for an additional 24 h. Firefly and Renilla luciferase activities were determined using 
the Dual-Luciferase reporter assay system (Promega). The activity of Renilla luciferase was used 
as an internal control for transfection efficiency. 
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Figure 2-1. Schematic diagram of the proteolytic processing of Dll1. The full length Dll1 (FL 
Dll1, 90kDa, yellow) is cleaved by ADAM12 (red) to generate the C-terminal Dll1 fragment 
(CTF Dll1, 29kDa, yellow) and the N-terminal fragment of Dll1 (NTF Dll1, 60kDa, yellow). The 
CTF Dll1 containing the transmembrane and intracellular domain is then cleaved by γ-secretase 
(orange) to produce the intracellular domain of Dll1 (ICD Dll1, 26kDa, yellow). The soluble 
NTF Dll1 is released to medium. 
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Figure 2-2. Proteolytic processing of Dll1 by ADAM12 increases Notch signaling in a cell-
autonomous manner. A, NIH3T3 cells were co-transfected with mouse Notch1 and either a 
CBF1 reporter (CBF1-Luc; pJH23A) or the same reporter in which CBF1 binding sites were 
mutated (Mut CBF1-Luc; pJH25A). After 24 h, cells were co-cultured with CHO cells stably 
transfected with vector only (CHO.Vec; white bars) or with CHO-cells stably transfected with 
Dll1 (CHO.Dll1; black bars). The activities of firefly luciferase, normalized to Renilla luciferase 
as internal control, were assayed 24 h later. B, NIH3T3 cells were transiently co-transfected with 
Notch1, a CBF1 reporter (pJT123A) and Dll1, wild type ADAM12 (A12), or catalytically 
inactive ADAM12 (E349Q A12) as indicated. After 24 h, cells were co-cultured for an additional 
24 h with CHO.Vec (white bars) or CHO.Dll1 cells (black bars) followed by measurement of 
luciferase activity. Notice that co-expression of Dll1 with Notch in the same cell inhibits Notch 
signaling induced by CHO.Dll1 (black bars) in the absence of A12 or in the presence of the 
E349Q mutant (*, p<0.05). In the presence of catalytically active A12 the inhibition was 
diminished and was not statistically significant. In A and B, error bars represent S.E. of the mean 
(n = 3). 
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Figure 2-3. Proteolytic processing of Dll1 by ADAM9, -12 and -17 increases Notch signaling 
in a cell-autonomous manner. NIH3T3 cells were transiently co-transfected with Notch1, a 
CBF1 reporter (pJT123A) and the empty pIRES-puro vector or Dll1, the empty pCDNA3.1 
vector (Vec, black), ADAM9 (A9, blue), ADAM12 (A12, purple), ADAM15 (A15, green) or 
ADAM17 (A17, yellow) as indicated. After 24 h, cells were co-cultured for an additional 24 h 
with CHO.Vec or CHO.Dll1 cells followed by measurement of luciferase activity. Notice that 
co-expression of Dll1 with Notch in the same cell inhibits Notch signaling induced by co-culture 
with CHO.Dll1 cells in the empty pCDNA3.1 vector-transfected NIH3T3 cells. In the presence 
of A9, A12 and A17 the inhibition was diminished (*, p<0.05), while in presence of A15, the 
inhibition remained. Error bars represent S.E. of the mean (n = 3). 
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Figure 2-4. Endogenous ADAM9 and/or ADAM12 contribute to Dll1 cleavage in MEFs. 
SV40-immortalized MEFs isolated from wild type mice (wt) or from ADAM9/12/15-/- triple 
knock-out mice (T) were transiently transfected to express Dll1 as indicated. A, after 48 h, Dll1 
processing was analyzed by Western blotting with anti-Dll1 antibody. The intensities of the 
bands corresponding to FL Dll1 were determined after short exposure times (left), and the 
intensities of the bands representing CTF Dll1 were measured after long exposure times (right). 
The amounts of FL Dll1 and CTF Dll1 in T-MEFs were normalized to the amounts in wt-MEFs; 
the results (mean from three different experiments, ± S.E.) are shown below each Western blot. 
B, 24 h after transfection cells were metabolically labeled with [35S]methionine + cysteine, and 
16 h later cell lysates were subjected to immunoprecipitation using anti-Dll1 antibody, as 
indicated. The immunoprecipitates were resolved by SDS-PAGE and analyzed by 
autoradiography. The intensities of the bands corresponding to FL Dll1 and CTF Dll1 were 
determined after short exposure times (left) and long exposure times (right), respectively, and the 
results were plotted as in A (mean ± S.E., n = 2). In A and B, cells were incubated for 6 h in the 
presence of 1 µM γ-secretase inhibitor L685,458 before harvesting. 
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Introduction  
S
T
keletal muscle development and regeneration in vertebrates requires a careful balance 
between myogenic differentiation and the maintenance of progenitor cells (Buckingham, 2006). 
During embryonic development, myogenic progenitor cells give rise to myoblasts that further 
undergo skeletal muscle differentiation. A population of progenitor cells is set aside and later 
these progenitors generate satellite cells. Satellite cells are the primary stem cells of post-natal 
skeletal muscle (Dhawan and Rando, 2005; Collins, 2006; Shi and Garry, 2006; Zammit et al., 
2006; Le Grand and Rudnicki, 2007). During muscle growth or regeneration after injury, 
quiescent satellite cells become activated, proliferate, and then either differentiate or return to the 
satellite quiescent state. The ability to adopt two divergent fates, differentiation or entry into an 
un-differentiated quiescent state, is maintained by myogenic cells in vitro. Studies utilizing 
isolated myofibers or myogenic cell cultures show that activated, proliferating satellite cells 
express both Pax7, a paired-box transcription factor, and MyoD, a basic helix-loop-helix 
myogenic determination factor. Some cells then down-regulate Pax7, maintain MyoD, and 
differentiate, and some cells down-regulate MyoD, maintain the expression of Pax7, and remain 
un-differentiated (Halevy et al., 2004; Zammit et al., 2004). Since quiescent Pax7+/MyoD- cells 
generated in vitro resemble quiescent satellite cells, the mechanisms regulating the generation of 
the pool of Pax7+/MyoD- cells may be similar to the mechanisms involved in satellite cell self-
renewal (Zammit et al., 2004). Consistently, in the absence of MyoD, satellite cells show an 
increased propensity for self-renewal rather than differentiation, which results in a deficit in 
muscle regeneration (Megeney et al., 1996; Sabourin et al., 1999; Yablonka-Reuveni et al., 
1999). 
he Notch pathway is an evolutionary conserved signaling mechanism that plays critical 
roles in cell fate decisions during embryonic development and in the adult. The pathway is 
activated when one of the Notch ligands, a transmembrane protein present at the surface of a 
signal-sending cell, binds to a Notch receptor present in a signal-receiving cell. In mammals, 
there are five Notch ligands, (Delta-like 1, 3, and 4, and Jagged 1 and 2) and four Notch 
receptors (Notch 1-4). The ligand-receptor interaction is followed by the sequential cleavage of 
the receptor by an ADAM protease and by γ-secretase, leading to the release of the intracellular 
domain of Notch, NICD, from the plasma membrane and its translocation to the nucleus. Inside 
the nucleus, NICD forms a complex with the transcription factor CBF1 (also known as RBP-J) 
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and the coactivator Mastermind, and it activates target gene expression (Kadesch, 2004; Bray, 
2006; Hurlbut et al., 2007). 
T
T
he Notch pathway is a critical regulator of myogenesis in cultured myogenic cells, in 
vertebrate embryos, and in post-natal regenerating muscle (Luo et al., 2005; Vasyutina et al., 
2007a). Early muscle development, as well as activation of satellite cells upon muscle injury, are 
accompanied by activation of Notch 1 signaling (Conboy and Rando, 2002; Brack et al., 2008). 
Notch signals inhibit myogenesis by blocking the expression and activity of the myogenic 
determination factor MyoD (Kopan et al., 1994; Shawber et al., 1996; Kuroda et al., 1999; 
Wilson-Rawls et al., 1999). Consequently, manipulations that activate the Notch pathway inhibit 
myogenic differentiation and manipulations that decrease the level of Notch signaling promote 
differentiation. Ectopic expression of a constitutively active form of Notch 1 in myogenic cells 
cultured in vitro (Kopan et al., 1994; Shawber et al., 1996; Conboy and Rando, 2002) or co-
culture of myogenic cells with cells overexpressing Notch ligands (Lindsell et al., 1995; Shawber 
et al., 1996; Jarriault et al., 1998; Kuroda et al., 1999) blocks myogenic differentiation. 
Overexpression of Numb, a negative regulator of Notch (Conboy and Rando, 2002; Kitzmann et 
al., 2006), or inhibition of γ-secretase activity (Kitzmann et al., 2006) promotes cell 
differentiation. Constitutive activation of Notch signaling in muscle cells during chick limb 
development by overexpression of Delta1 prevents MyoD expression and leads to inhibition of 
myogenesis in vivo (Delfini et al., 2000; Hirsinger et al., 2001). Furthermore, myoblasts lacking 
Stra13, a basic helix-loop-helix transcription factor that modulates Notch signaling, exhibit 
increased proliferation and defective differentiation (Sun et al., 2007). Megf10, a novel multiple 
epidermal growth factor repeat transmembrane protein that impinges on Notch signaling 
stimulates myoblast proliferation and inhibits differentiation (Holterman et al., 2007). 
wo recent studies have directly established that Notch signaling is critical for muscle 
development in the mouse. These studies also revealed that in addition to being a negative 
regulator of myogenic differentiation, Notch is a positive and essential regulator of muscle 
progenitor cells. First, Dll1 hypomorph mutant mice show premature myoblast differentiation in 
the embryo, depletion of progenitor cells, and severe muscle hypotrophy (Schuster-Gossler et al., 
2007). Second, conditional mutagenesis of RBP-J in mice results in a similar premature 
differentiation, depletion of progenitor cells, and lack of muscle growth (Vasyutina et al., 
2007b). Both studies indicate that Notch signaling initiated by Dll1 ligand and mediated by RBP-
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J is essential for maintaining a resident pool of myogenic progenitor cells and preventing their 
differentiation during muscle development. In the adult, Notch plays an important role in satellite 
cell expansion during muscle regeneration, and inadequate Notch signaling caused by reduced 
expression of Dll1 in aging muscle contributes to the loss of its regenerative potential (Conboy et 
al., 2003). 
In
W
In
 summary, it appears that the two pools of cells that are generated simultaneously during 
myogenesis in vivo or in tissue culture, i.e., terminally differentiated cells and undifferentiated 
cells with progenitor-like properties, have opposing requirements for Notch signaling. While 
Notch activation must be relieved in cells progressing into differentiation, Notch signaling must 
be sustained (or elevated) in progenitors/self-renewing satellite cells/reserve cells to prevent their 
differentiation. The mechanisms responsible for the regulation of Notch activity in a population 
of myogenic cells are not well understood. 
e and others have shown that, in certain cell systems, the extracellular domains of several 
Notch ligands, including Dll1, are shed from the cell surface by ADAM proteases (Ikeuchi and 
Sisodia, 2003; Six et al., 2003; Dyczynska et al., 2007). Ligand shedding down-regulates Notch 
signaling in neighboring cells (Mishra-Gorur et al., 2002) and may stimulate Notch signaling in a 
cell-autonomous manner (Dyczynska et al., 2007). Modulation of the Notch pathway by ligand 
shedding plays an important role in the developing wing in Drosophila (Sapir et al., 2005) and in 
cortical neurogenesis in mice (Muraguchi et al., 2007). The extent of ligand shedding and its 
potential role in modulating Notch signaling during myogenic differentiation has not been 
examined. 
 this study, we show that Notch signaling is required for maintaining Pax7 expression in 
cultures of differentiating mouse primary myoblasts and C2C12 cells. Furthermore, stimulation 
of Notch activity increases expression of Pax7 and, consistent with previous reports, inhibits 
myogenic differentiation. Dll1 is proteolytically processed in a pool of C2C12 reserve cells that 
are Pax7-positive, quiescent and un-differentiated, but Dll1 remains intact in differentiated 
myotubes. Incubation of primary myoblasts or C2C12 cells with a soluble, dominant-negative 
mutant form of ADAM12 leads to inhibition of Dll1 cleavage, elevation of Notch signaling, 
expansion of the pool of Pax7+/MyoD- cells, and reduction of the number of Pax7+/MyoD+ cells. 
We propose that the proteolytic processing of Dll1, a stochastic event, helps achieve an 
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asymmetry in Notch signaling in a pool of initially equivalent myogenic cells and helps sustain 
the balance between differentiation and maintenance of undifferentiated cells. 
 
Results 
It
T
 has been shown previously that Notch is activated during satellite cell activation in vivo, 
and that active Notch is present in proliferating primary myoblasts in vitro, where it enhances 
myoblast proliferation and inhibits differentiation (Conboy and Rando, 2002). We examined the 
amount of active Notch in cultures of myogenic cells at the stage when most of the cells exit the 
cell cycle and undergo differentiation. Primary mouse myoblasts or C2C12 mouse myogenic 
cells were incubated in growth medium (GM) containing 10% FBS for 24-48 hours until they 
were 90-100% confluent, then they were transferred to differentiation medium (DM) containing 
2% HS and were incubated for additional 3 days. Early differentiation markers myogenin and 
cell cycle inhibitor p21 increased during incubation of cells in DM, indicating that some cells 
progressed into differentiation (Fig.3-1A). MyoD and Pax7, a marker of non-differentiating cells, 
were expressed in cells in GM and remained high in cells incubated in DM (Fig.3-1A). The 
number of proliferating primary cells that incorporated BrdU after the 3-hour pulse labeling 
decreased from ~55% at day 0 to ~10% at day 3 in DM, and the number of BrdU-labeled C2C12 
cells decreased from ~70% at day 0 to ~5% at day 3 (Fig.3-1B). Importantly, the level of active 
Notch 1, determined by Western blotting using epitope-specific anti-Notch 1 antibody that 
recognizes NICD only after Notch 1 is cleaved by γ-secretase, declined much less dramatically 
(by ~15% in primary cells and by ~40% in C2C12 cells) between day 0 and day 3 in DM (Fig.3-
1AB). After separation of Pax7- differentiated C2C12 myotubes from Pax7+ undifferentiated 
reserve cells at day 3, NICD was detected exclusively in the reserve cells fraction (Fig.3-1C). 
These results suggest that there is no direct correlation between the number of proliferating cells 
and the total Notch activity in cultures of differentiating myogenic cells. Instead, Notch 1 
remains active in a population of Pax7+ cells that have stopped proliferation and remain 
undifferentiated. 
o examine the role of Notch in maintaining the pool of Pax7+ cells, primary myoblasts 
were incubated for 1 day in DM in the presence of GM6001, a broad-spectrum metalloproteinase 
inhibitor (Grobelny et al., 1992), or DAPT, a potent and selective inhibitor of γ-secretase activity 
(Dovey et al., 2001). GM6001, by inhibiting ADAM-mediated cleavage of Notch at the S2 site, 
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prevents the subsequent cleavage at the S3 site by γ-secretase, whereas DAPT directly blocks 
cleavage and activation of Notch by γ-secretase. Indeed, as shown in Fig.3-2A, both GM6001 
and DAPT treatment effectively eliminated the active Notch 1, NICD. After treatment with 
DAPT, the levels of MyoD, myogenin, and p21 were slightly increased, consistent with 
stimulation of myogenic differentiation upon inhibition of Notch activity (Conboy and Rando, 
2002; Kitzmann et al., 2006). Notably, both GM6001 and DAPT dramatically decreased the 
expression level of Pax7 (Fig.3-2AB), indicating an absolute requirement for the active Notch in 
the maintenance of Pax7-positive cells. Interestingly, the level of Pax3, the paralogue of Pax7 
with partially overlapping functions in myogenic cells (Relaix et al., 2006; Buckingham and 
Relaix, 2007), was not strongly affected by DAPT treatment (Fig.3-2A). Inhibition of Notch by 
DAPT in C2C12 cells produced similar effects, although inhibition of Pax7 expression was not 
as potent as in primary myoblasts (Fig.3-2C). 
T
T
o explore whether increasing Notch activity has any effect on Pax7, we first infected 
primary myoblasts with retroviruses encoding a constitutively active Notch 1, caNotch. caNotch 
lacks a major portion of the extracellular domain and is processed to NICD in a ligand-
independent manner (Ohtsuka et al., 1999). In contrast to the endogenous NICD which is very 
hard to visualize by immunofluorescence microscopy (Schroeter et al., 1998), the exogenous 
NICD can be easily detected in the nuclei of infected cells. We observed that the number of 
Pax7+ cells was ~2-fold higher among NICD-positive than NICD-negative cells on the same 
microscopic slide (Fig.3-3A). Pax7 expression was not changed in cells infected with control 
virus (bearing a truncated, inactive Notch 1, detected with anti-FLAG antibody; Fig.3-3A).  In an 
alternative approach to stimulate the Notch pathway, primary myoblasts or C2C12 cells were co-
cultured with CHO cells stably transfected with mouse Dll1 or with empty vector (Dyczynska et 
al., 2007). As reported previously (Lindsell et al., 1995; Shawber et al., 1996; Jarriault et al., 
1998; Kuroda et al., 1999), co-culture with Dll1-transfected cells inhibited myogenic 
differentiation, as judged by decreased expression of MyoD and myogenin (Fig.3-3B). 
Importantly, the level of Pax7 both in primary myoblasts and in C2C12 cells co-cultured with 
Dll1-transfected CHO cells was dramatically increased (Fig.3-3B). Collectively, these results 
indicate that Notch is a critical regulator of the balance between Pax7+ and Pax7- cells. 
he requirement for the active Notch in Pax7-positive cells and decline of Notch activity in 
differentiating cells suggest that there must be a heterogeneity in Notch signaling among post-
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mitotic myogenic cells cultured in vitro. To get insight into possible mechanisms responsible for 
the heterogenic levels of Notch signaling, we examined the expression, distribution, and 
proteolytic processing of Dll1, a Notch ligand that plays critical roles in muscle development in 
vivo (Schuster-Gossler et al., 2007). Similar to the proteolytic processing of Notch, mammalian 
Dll1 undergoes a sequential cleavage by ADAM proteases and then by γ-secretase (Ikeuchi and 
Sisodia, 2003; Six et al., 2003; a diagram is depicted in Fig.3-4A). The immediate consequence 
of ADAM-mediated shedding of the extracellular domain of Dll1 is down-regulation of Notch 
signaling in neighboring cells (Mishra-Gorur et al., 2002; Muraguchi et al., 2007; Sapir et al., 
2005) and, possibly, activation of Notch signaling in the same cell (Dyczynska et al., 2007). We 
have previously observed a cleaved form of the endogenous Dll1 in cultures of primary 
myogenic cells (Dyczynska et al., 2007). Here, we have used cultures of C2C12 cells incubated 
for 3 days in DM to separate well-differentiated myotubes (Pax7-negative, low Notch activity) 
from reserve cells (Pax7-positive, high Notch activity; see Fig.3-1C). When total cell extract was 
subjected to Western blotting using antibody specific for the C-terminus of Dll1, three Dll1 
bands were detected: the ~90-kDa full-length form (Dll1FL), the 29-kDa ADAM-cleavage 
product spanning the transmembrane and the intracellular domains of Dll1 (Dll1TMIC), and the 
26-kDa γ-secretase cleavage product comprising the intracellular domain and a short C-terminal 
segment of the transmembrane domain (Dll1IC). Remarkably, after separation into the myotube 
and reserve cell fractions, Dll1TMIC and Dll1IC were present only in reserve cells, and no Dll1TMIC 
or Dll1IC were observed in myotubes (Fig.3-4B). In contrast, Dll1FL was more abundant in 
myotubes than in reserve cells (Fig.3-4B). This indicates that the proteolytic processing of Dll1 
in differentiating C2C12 cells is asymmetrical, with significantly more cleavage detected in 
Pax7-positive reserve cells than in Pax7-negative myotubes. 
To determine whether the asymmetrical cleavage of Dll1 in Pax7-positive vs Pax7-negative 
cells is a mere consequence of different proteolytic activities in these two populations of cells or 
whether it plays a more direct, causal role in establishing an imbalance in Notch signaling and 
generating two pools of myotubes and reserve cells, we intended to inhibit ADAM-mediated 
cleavage of Dll1, the first and obligatory step in Dll1 processing. Since several different ADAM 
proteases expressed in myogenic cells are capable of cleaving Dll1, including ADAM9, 10, 12, 
and 17 (Dyczynska et al., 2007), and since ADAM10 and ADAM17 also cleave Notch (Brou et 
al., 2000; Hartmann et al., 2002; Mumm et al., 2000), we adopted a dominant-negative approach 
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rather than knocking down expression of individual ADAMs or using pharmacological inhibitors 
of ADAM activities. We showed previously that ADAM12 cleaves Dll1 but it does not process 
Notch, and that ADAM12 forms complexes with Dll1 (Dyczynska et al., 2007). Here, we used 
the soluble extracellular domain of the catalytically inactive mutant form of ADAM12, 
expressed and purified from Drosophila S2 cells (recombinant protein X, Fig.3-5A), to block the 
processing of Dll1 by endogenous ADAM proteases. When COS-7 cells were transfected to 
express murine Dll1, the Dll1FL and Dll1TMIC forms were observed in Western blots (Fig.3-5B; 
Dll1TMIC is the predominant cleaved form and Dll1IC is poorly detected when Dll1 is 
overexpressed (Ikeuchi and Sisodia, 2003; Six et al., 2003; Dyczynska et al., 2007)). In the 
presence of exogenously added purified protein X, the extent of Dll1 cleavage was reduced by 
~50% (Fig.3-5B), which validated the use of protein X as a dominant-negative modulator of Dll1 
cleavage. In primary myoblasts incubated for 1 day in differentiation medium containing protein 
X, the level of Notch signaling was increased, as demonstrated by the elevated amount of NICD 
(Fig.3-5C.a). Furthermore, a higher transcriptional activity of the CBF1-luciferase reporter gene 
was observed in primary myoblasts or C2C12 cells incubated in the presence of protein X (Fig.3-
5C.b). Our interpretation of these results is that protein X, by binding to Dll1, prevents its 
cleavage by ADAMs but it does not interfere with Dll1 binding and activation of Notch in trans. 
Thus, higher level of Notch activity in the presence of protein X suggests that ADAM-mediated 
shedding of Dll1 contributes to down-regulation of Notch signaling in a pool of cells during 
myogenic differentiation in vitro. 
Down-regulation of Dll1 cleavage by protein X had also a negative effect on the 
progression through a myogenic lineage, as the total levels of MyoD, myogenin, and p21 were 
decreased by ~50%, 25%, and 25%, respectively (Fig.3-6A). In contrast, expression of Pax7 was 
slightly increased after 1 day incubation of cells in differentiation medium containing protein X 
(Fig.3-6A). The effect of protein X on the level of MyoD, myogenin, p21, and Pax7 were 
abolished in the presence of γ-secretase inhibitor DAPT (Fig.3-6A), suggesting that the effect of 
protein X was mediated through the activation of Notch signaling, as shown in Fig.3-5C. Similar 
inhibition of MyoD, myogenin, and p21 expression and elevation of Pax7 expression was 
observed in C2C12 cells upon incubation of cells in DM supplemented with protein X (Fig.3-
6B). Furthermore, immunofluorescence analysis of cells using anti-MyoD and anti-Pax7 
antibody demonstrated that protein X specifically decreased the pool of Pax7+/MyoD+ myoblasts 
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and increased the pool of Pax7+/MyoD- myoblasts, whereas the pool of Pax7-/MyoD+ myoblasts 
did not seem to be affected (Fig.3-6C). These results suggest that the shedding of Dll1, which is 
partially blocked in the presence of protein X, is important in maintaining the balance between 
Pax7+/MyoD+ and Pax7+/MyoD- cells. 
 
Discussion 
T
It
O
his study provides an insight into the role of Notch signaling in sustaining the balance 
between myogenic differentiation and the maintenance of undifferentiated cells in vitro. Our 
studies suggest that the proteolytic processing of Dll1, a Notch ligand, plays an important role in 
modulation of Notch signaling and myogenic cell fate determination. 
 has been previously shown that the Notch pathway is critical for satellite cell activation 
and myogenic precursor cell expansion in postnatal myogenesis (Conboy and Rando, 2002). 
New genetic evidence indicates that Notch signaling initiated by Dll1 and mediated by RBP-J is 
essential for maintaining a pool of myogenic progenitor cells and for preventing their 
differentiation during muscle development in mice (Schuster-Gossler et al., 2007; Vasyutina et 
al., 2007b). In accordance with these studies, we find that Notch signaling is critical in 
maintaining expression of Pax7, a marker of the undifferentiated state, in quiescent myoblasts in 
vitro. Inhibition of the Notch pathway using pharmacological inhibitors of either ADAM 
proteases (GM6001) or γ-secretase (DAPT) abolishes Pax7 expression, and stimulation of Notch 
signaling expands the pool of Pax7+ cells. 
ur results differ from those obtained by Conboy and Rando, where down-regulation of 
Notch signaling in differentiating myoblast by retrovirally delivered Notch antagonist Numb did 
not have an effect on the level of Pax7 (Conboy and Rando, 2002). It is possible that application 
of pharmacological inhibitors of the Notch pathway in our studies might have resulted in a more 
complete and uniform inhibition of Notch signaling than expression of Numb. Our results are 
more in line with the study by Kuang et al., in which treatment of freshly isolated proliferating 
satellite cells with DAPT for 3 days of culture significantly reduced the total number of cells due 
to a decrease of the number of Pax7+/MyoD- cells (Kuang et al., 2007). While the results of 
Kuang et al. further support the notion that Notch signaling is vital for satellite cell expansion, 
our results indicate that Notch is also required to maintain Pax7 expression in a pool of quiescent 
myoblasts, after they exit the cell cycle. Interestingly, forced expression of Delta1 and activation 
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of the Notch pathway during early avian myogenesis in vivo resulted in down-regulation of 
MyoD and complete lack of differentiated muscles, but the exit from the cell cycle was not 
blocked, suggesting that Notch signaling acts in post-mitotic myogenic cells to control a critical 
step of muscle differentiation (Delfini et al., 2000; Hirsinger et al., 2001). Thus, Notch signaling 
acts at multiple steps of the muscle development and regeneration processes. 
W
If
e propose a model in which the level of Notch activity plays a crucial role in cell fate 
determination after myoblasts exit the cell cycle (Fig.3-7). According to this model, the Notch 
pathway is turned on in activated, proliferating satellite cells that are Pax7+/MyoD+. Upon cell 
cycle exit, Notch signaling is down-regulated in a subset of Pax7+/MyoD+ cells and it is 
maintained (or further up-regulated) in self-renewing Pax7+/MyoD- cells that replenish the pool 
of satellite cells. As Pax7+/MyoD+ cells progress into differentiation, they express myogenin, a 
negative regulator of Pax7 expression (Olguin et al., 2007), and become Pax7-negative. The loss 
of Pax7-positive cells in DAPT-treated cultures may thus be related to the effect of Notch on 
MyoD: low levels of Notch signaling promote high MyoD, induction of myogenin and, in 
consequence, loss of Pax7. In contrast, expansion of Pax7-positive cells observed after 
stimulation of the Notch pathway may be a consequence of decreased MyoD and myogenin 
expression. If this is the case, modulation of Pax7 expression by Notch signaling should be 
blunted in MyoD-/- myoblasts, a prediction that remains to be tested. To our knowledge, Pax7 is 
not directly regulated by any of the known Notch target genes. 
 the level of Notch signaling is set at different levels in Pax7-/MyoD+ and Pax7+/MyoD- 
cells, the question remains: How are these different levels of Notch signaling simultaneously and 
spontaneously achieved in two pools of initially equivalent myogenic cells? One mechanism 
could involve an asymmetric cell division that generates two daughter cells: one with a high 
Notch activity and one with a low Notch activity (Kuang et al., 2008). Numb is distributed 
asymmetrically during satellite cell division and it has been postulated that the cell inheriting 
Numb is the one that acquires low Notch activity and proceeds into differentiation (Conboy and 
Rando, 2002). However, Numb has been also shown to be asymmetrically segregated to cells 
that inherit all the older template DNA strands (Shinin et al., 2006), suggesting that Numb-
receiving cells are self-renewing (according to the immortal DNA strand hypothesis; Cairns, 
1975), rather than differentiating ones. Furthermore, the level of Numb increases significantly 
after the onset of differentiation (Conboy and Rando, 2002) and, in chick embryo, it is promoted 
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by MyoD expression (Holowacz et al., 2006). This pattern of Numb expression suggests that 
Numb may reinforce, rather than initiate, the low Notch activity in differentiating cells. In 
addition, the results presented here and in several other reports (Lindsell et al., 1995; Shawber et 
al., 1996; Jarriault et al., 1998; Kuroda et al., 1999) have demonstrated that co-culture of 
myoblasts with Dll1- or Jagged1-overexpressing cells inhibits myogenic differentiation, 
suggesting that limited ligand availability rather than Numb, may be responsible for the decline 
of Notch activity in differentiating myogenic cells. 
R
A
ecent studies indicate that satellite cells are a mixture of stem cells and committed 
myogenic progenitors (Collins, 2006; Kuang et al., 2007; Zammit et al., 2006) and that 
asymmetric division of stem cells in vivo yields one stem cell and one committed daughter cell 
(Kuang et al., 2007). The two daughter cells show asymmetric expression of Dll1, with higher 
Dll1 level (and most likely lower Notch activity) in the committed cell. This asymmetric cell 
division is favored by a specific stem cell niche and it occurs perpendicular to the muscle fiber, 
with Dll1 being expressed in the cell that maintains contact with the plasmalemma (Kuang et al., 
2007). Whether such oriented cell division with asymmetric expression of Dll1 takes place in 
satellite cells cultured in vitro and deprived of the niche regulation is not clear. It appears that the 
modulation of Notch signaling among cells cultured in vitro may be achieved in large part by 
stochastic mechanisms (Losick and Desplan, 2008). We propose that one of these mechanisms 
involves the proteolytic processing of Dll1 by ADAM proteases (Fig.3-7), a hypothesis 
supported by two observations. First, in C2C12 cells, we detect the cleaved Dll1 in 
undifferentiated reserve cells but not in differentiated myotubes. Second, inhibition of Dll1 
processing by soluble, catalytically inactive extracellular domain of ADAM12, protein X, 
elevates the global Notch signaling and increases the pool of Pax7+/MyoD- cells, with the 
concomitant decrease of the pool of Pax7+/MyoD+ cells (Figs.3-5 and 3-6). These studies 
confirm and extend our previous observations obtained for C2C12 cells, where the soluble 
protein X inhibited myogenic differentiation (Yi et al., 2005) and overexpression of the wild-
type ADAM12 decreased MyoD expression (Cao et al., 2003). 
ccording to the model in Fig.3-7, Dll1 shedding helps establish a balance between 
Pax7+/MyoD+ and Pax7+/MyoD- cells after the exit from the cell cycle. Proteolytic processing of 
Dll1 by ADAMs in some cells leads to ligand depletion and down-regulation of Notch signaling 
in neighboring cells. Cells in which Dll1 cleavage takes place would acquire higher level of 
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Notch activity than their neighbors, leading to down-regulation of MyoD. Cells in which the 
cleavage of Dll1 does not occur or occurs less efficiently would attain lower level of Notch 
signaling and maintain MyoD expression. Inhibition of Dll1 processing by soluble protein X did 
not seem to have a direct effect on the number of Pax7-/MyoD+ cells (Fig.3-6C), and thus the 
balance between Pax7+/MyoD+ and Pax7-/MyoD+ cells may not be controlled by the cleavage of 
Dll1. Furthermore, since MyoD is a positive regulator of Delta-1 in Xenopus (Wittenberger et al., 
1999), it is possible that MyoD stimulates Dll1 expression and further up-regulates Notch 
signaling in neighboring Pax7+/MyoD- cells. This would provide another means to increase Dll1 
expression in cells with declining Notch activity, in addition to the relief of the transcriptional 
repression mediated by Notch (Greenwald, 1998; Wilkinson et al., 1994). Stimulation of Numb 
expression by MyoD (Holowacz et al., 2006), on the other hand, should down-regulate Notch 
and further consolidate the differences in Notch signaling among MyoD+ and MyoD- cells. 
W
D
hile other stochastic models of myogenic cell fate determination invoke random changes 
in the level of expression of the Notch pathway components, myogenic factors, or Pax7, we 
place the main emphasis on the proteolytic processing of Dll1 as the initial trigger of the 
asymmetry in Notch signaling between seemingly equivalent cells. Since Dll1 cleavage occurs at 
the cell surface, is cell-density dependent, and may be influenced by intracellular events 
(Dyczynska et al., 2007; Zolkiewska, 2008), it combines features of a stochastic, as well as 
regulated mechanism of Notch modulation. Finally, our model is not mutually exclusive with 
oriented cell division, which may be most relevant in vivo where it becomes subject to niche 
regulation. The extent to which Dll1 shedding contributes to the regulation of Notch signaling 
and myogenic cell fate determination during muscle development, growth, and regeneration in 
vivo remains to be determined. 
 
Materials and Methods 
Expression constructs 
ll1-pcDNA3.1 expression vector has been described previously (Dyczynska et al., 2007; 
2008). Notch reporter vector containing eight CBF-1 binding sites (pJT123A) was provided by 
P. D. Ling (Baylor College of Medicine). caNotch-AP retroviral vector directed expression of the 
constitutively active mouse Notch 1 spanning the transmembrane region, the RAM23 domain, 
the cdc10/ankyrin repeats, and the nuclear localization signal (aa 1704-2192), and c-AP vector 
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lacking the RAM23 and cdc10/ankyrin repeats sequences, was a negative control (Ohtsuka et al., 
1999). caNotch-AP and c-AP vectors were obtained from R. Kageyama and C. Takahashi (Kyoto 
University). 
 
Cells 
C
T
2C12 and COS-7 cells were obtained from American Tissue Culture Collection; 
Drosophila S2 cells were from Invitrogen; the retroviral packaging cell line Phoenix Eco was 
provided by Dr. Garry P. Nolan (Stanford University). C2C12, COS-7, and Phoenix Eco cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum (FBS) at 37˚C in the presence of 5% CO2 under a humidified atmosphere. CHO 
cells stably transfected with mouse Dll1 or with empty vector were grown in F12K nutrient 
mixture supplemented with 10% FBS and 800 µg/ml G418, as described (Dyczynska et al., 
2007). Drosophila S2 cells were cultured at 27˚C in Schneider’s Drosophila medium containing 
10% heat inactivated FBS. Primary myoblasts were isolated from hindlimbs and forelimbs of 
neonatal C57BL/6 mice (2-5 days old) as described (Rando and Blau 1994). The muscle tissue 
was incubated in Dulbecco’s phosphate-buffered saline (DPBS) with 1% collagenase II 
(Invitrogen), 2.4 U/ml dispase II (Roche) and 2.5 mM CaCl2 for 45 minutes at 37˚C, and then 
passed through 100-µm nylon mesh filter (BD Biosciences). The filtrate was centrifuged, the cell 
pellet was suspended in Ham’ F-10 medium (Cambrex) containing 20% FBS and 1% 
penicillin/streptomycin, pre-plated for 30 minutes on collagen I-coated plates, and then plated on 
tissue culture-treated plastic plates. To stimulate differentiation, 90-100% confluent primary 
myoblasts or C2C12 cells were transferred to DMEM containing 2% horse serum. 
 
Plasmid transfection and retroviral infection  
ransient transfections were performed using Fugene 6 transfection reagent (Roche 
Applied Science) according to the manufacturer’s protocol, one day after plating cells. For 
generation of retroviruses, virus packaging Phoenix Eco cells were transfected with a retroviral 
expression vector (15 µg plasmid DNA per 100-mm plate) using calcium phosphate precipitation 
method, viral supernatants were harvested 48 hours later, supplemented with 5 µg/ml polybrene, 
and used to infect primary myoblasts. 
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Protein expression and purification 
T
P
 
D
he cDNA fragment encoding the extracellular domain of ADAM12 (protein X, amino 
acids 32–707, containing the E349Q mutation) was cloned into the pMT/BiP/V5-HisA vector 
(Yi et al. 2005). Drosophila S2 cells stably transfected with protein X (Yi et al. 2005) were 
incubated for 5 days in the presence of 0.5 mM CuSO4. Culture medium was collected 5 days 
later, and protein X was purified by sequential chromatography on a chelating Sepharose column 
(Amersham Biosciences) and a nickel-nitrilotriacetic acid-agarose column (Qiagen) (Yi et al., 
2005). The final column eluate was dialyzed against DMEM, supplemented with 2% HS or 10% 
FBS, and added to cells. 
 
Cell treatments 
rimary myoblasts were cultured in growth medium until 90%-100% confluency and then 
they were incubated for 24 hours in differentiation medium (DMEM plus 2% horse serum) with 
1 µM DAPT (Calbiochem), 5 µM GM6001 (Chemicon; both dissolved in DMSO), or DMSO 
alone. Confluent C2C12 cells were incubated for 1 day in DM with 5 µM DAPT or DMSO. In 
the experiments analyzing the effect of protein X, medium was prepared by adding 2% HS (for 
primary myoblasts and C2C12 cells) or 10% FBS (for COS-7 cells) directly to the solution of 
protein X (final concentration: 2 µM) dialyzed against DMEM or to DMEM that was retrieved as 
the external dialysis solution. For analysis of cell proliferation, primary myoblasts or C2C12 
cells were incubated with 10 µM 5-Bromo-2'-deoxyuridine (BrdU) for 3 hours prior to fixation 
and staining with anti-BrdU antibody. For 35S -labeling, C2C12 cells were incubated for 3 days 
in DM and then for 16 h in methionine/cysteine-free DM containing EasyTag 200 µCi/ml 
Expre[35S][35S]-Protein Labeling Mix (PerkinElmer). 
Separation of myotubes and reserve cells 
ifferentiating cultures of C2C12 cells were separated into myotubes and reserve cells 
essentially as described earlier (Kitzmann et al., 1998; Cao et al., 2003). C2C12 cells were 
incubated for 3 days in DM and subjected to mild trypsinization (0.05% trypsin and 1 mM 
EDTA in DPBS, 1 minute treatment). Detached myotubes were collected first and the remaining 
undifferentiated reserve cells were detached by 5 min incubation with 0.25% trypsin and 1 mM 
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EDTA in DPBS. The purity of the myotube and reserve cell fractions was assessed by Western 
blotting with anti-integrin α7A and anti-Pax7 antibodies, respectively. 
 
P
 
C
C
Cell co-culture experiments 
rimary myoblasts or C2C12 cells were plated in 6-well plates. One day later, when cells 
were ~70% confluent, CHO cells stably transfected with mouse Dll1 or empty vector were added 
(5 x 105 cells/well) and incubated in DM without G418. Twenty four hours later, cells were 
washed and 300 µl of extraction buffer was added to wells. 
Western blotting 
ells were incubated in extraction buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-sulfonyl 
fluoride hydrochloride (AEBSF), 5 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml pepstatin A, 10 
mM 1,10-phenanthroline) for 15 minutes at 4˚C. Cell extracts were centrifuged at 21,000xg for 
15 min, supernatants were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. 
The membrane was blocked in DPBS containing 3% (w/v) dry milk and 0.3% (v/v) Tween 20, 
then incubated with primary antibodies in blocking buffer, followed by incubation with 
horseradish peroxidase-labeled secondary antibodies and detection using the WestPico 
chemiluminescence kit (Pierce). The following primary antibodies were used: rabbit anti-Dll1 
(H-265, Santa Cruz Biotechnology, 1:200), mouse anti-p21 (F-5, Santa Cruz Biotechnology, 
1:1000), mouse anti-myogenin (F5D, Santa Cruz Biotechnology, 1:200), rabbit anti-MyoD (C-
20, Santa Cruz Biotechnology, 1:500), mouse anti-MyoD (5.8A, Lab Vision, 1:500), mouse anti-
Pax7 (ascites, Developmental Studies Hybridoma Bank, 1:250), mouse anti-Pax3 (ascites, 
Developmental Studies Hybridoma Bank, 1:500), rabbit anti-cleaved Notch 1 (Val1744, Cell 
Signaling, 1:500), mouse anti-α-tubulin (Sigma, 1:100,000), rabbit anti-integrin α7A (a gift from 
Stephen J. Kaufman, 1:2000). Secondary antibodies were horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse IgG antibodies. 
 
Immunofluorescence 
ells grown on glass coverslips or in plastic chamber wells were fixed with 3.7% 
paraformaldehyde in DPBS for 20 minutes and permeabilized with 0.1% Triton X-100 in DPBS 
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for 5 min. Cells were blocked in DPBS containing 5% donkey serum (v/v) and 1% BSA (w/v), 
then incubated with primary antibodies diluted in 1% BSA, followed by incubation with 
fluorophore-conjugated secondary antibodies. The primary antibodies used were: mouse anti-
Pax7 (supernatant, Developmental Studies Hybridoma Bank, 1:5), rabbit anti-MyoD (C-20, 
1:50), goat anti-desmin (Santa Cruz Biotechnology, 1:50), rabbit anti-cleaved Notch 1 (Val1744, 
1:50); rabbit anti-FLAG (Affinity BioReagents, 1:1000). For detection of BrdU-stained nuclei, 
fixed cells were treated with 70% ethanol and 50 mM glycine, pH 2.0, then with 4N HCl for 15 
minutes at room temperature to denature DNA, and then cells were stained with rat anti-BrdU 
antibody (Abcam, 1:100). Secondary antibodies were coupled Alexa488, rhodamine Red-X or 
AMCA. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Coverslips were 
mounted on slides and examined by Axiovert 200 inverted fluorescent microscope (Zeiss). 
 
Luciferase reporter assays 
Primary myoblasts or C2C12 cells grown in 96-well plates were transfected at 60% 
confluency with 0.05 µg CBF1 firefly luciferase gene reporter vector and 0.005 µg Renilla 
luciferase (pRL-TK) vector as an internal control for transfection efficiency. Twenty four hours 
after transfection, cells were transferred to DM. Firefly and Renilla luciferase activities were 
measured using the Dual-Luciferase reporter assay system (Promega) at day 0 and day 1 in DM. 
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Figure 3-1. Notch activity in myogenic cells during differentiation in vitro.  Primary mouse 
myoblasts or C2C12 cells were incubated in growth medium until they were 90-100% confluent 
(GM, Day0) and then they were transferred to differentiation medium (DM, Day1- Day3). (A) 
The levels of active Notch 1 (NICD), Pax7, MyoD, myogenin, p21, and tubulin were determined 
by Western blotting. NICD was detected using epitope-specific antibody against γ-secretase-
cleaved Notch 1. (B) The amount of NICD in panel A was quantified by gel densitometry and 
normalized to the amount of tubulin (black bars); the amount of NICD at Day0 is set as 1. 
Percent of BrdU-positive cells was determined after 3-hour pulse BrdU labeling (gray bars). 
Experiments in A and B were repeated three times with similar results, representative 
experiments for primary myoblasts and C2C12 are shown. (C) C2C12 cells incubated for 3 days 
in DM were subjected to partial trypsinization to separate myotubes (Mt, integrin α7A-positive) 
from reserve cells (RC, Pax7-positive). The amount of NICD in Mt and RC fractions and in total 
cell lysate was determined by Western blotting. 
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Figure 3-2. Notch activity is essential for the maintenance of Pax7-positive cells during 
myogenic differentiation in vitro. (A) Primary myoblasts, incubated in GM until 90-100% 
confluency, were transferred to DM and were incubated for 1 day in the presence of DMSO or 5 
µM GM6001, a metalloproteinase inhibitor (left), or in the presence of DMSO or 1 µM DAPT, a 
γ-secretase inhibitor (right). The levels of NICD, Pax7, Pax3, MyoD, myogenin, and p21 were 
determined by Western blotting, tubulin is a gel-loading control. A representative experiment out 
of three is shown. (B) Primary myoblasts incubated for 1 day in DM in the presence of DMSO, 5 
µM GM6001, or 1 µM DAPT were stained with mouse anti-Pax7 and goat anti-desmin 
antibodies, and then with Rhodamine Red-X conjugated anti-mouse IgG and AMCA-conjugated 
anti-goat IgG antibodies. (C) Confluent C2C12 cells were incubated for 1 day in DM in the 
presence of DMSO or 5 µM DAPT and the levels of NICD, Pax7, Pax3, MyoD, myogenin, p21, 
and tubulin were analyzed by Western blotting. 
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Figure 3-3. Notch stimulation expands Pax7-positive cells during myogenic differentiation 
in vitro. (A) Primary myoblasts were infected with retroviruses containing constitutively active 
mouse Notch 1 (caNotch-AP) or with control retroviruses (c-AP). One day after infection, cells 
were transferred to DM and, one day later, cells were fixed, co-stained with mouse anti-Pax7 and 
rabbit anti-cleaved Notch 1 (caNotch-AP-infected cells) or anti-FLAG antibodies (c-AP-infected 
cells), and analyzed by immunofluorescence microscopy. The relative number of Pax7-positive 
cells among NICD-negative and NICD-positive cells (or FLAG-negative and FLAG-positive 
cells) on the same slide was calculated (mean ± s.e.m., n=3; at least 200 Pax7-positive cells were 
counted in each determination). (B) Primary myoblasts or C2C12 cells (~70% confluent) were 
co-cultured for 1 day with CHO cells stably transfected with mouse Dll1 (CHO-Dll1) or with 
empty vector (CHO-V). The levels of NICD, Pax7, MyoD, myogenin, p21, and tubulin were 
analyzed by Western blotting. 
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Figure 3-4. Proteolytic processing of Dll1 in reserve cells. (A) Schematic diagram of the 
sequential cleavage of Dll1. The full-length Dll1 (Dll1FL, 90 kDa) is cleaved by an ADAM. The 
transmembrane and intracellular domain fragment (Dll1TMIC, 29 kDa) is then cleaved by γ-
secretase and the intracellular domain (Dll1IC, 26 kDa) is released. The γ-secretase-mediated 
cleavage is inhibited by DAPT, the antibody recognition site is located in the intracellular 
domain of Dll1. (B) Left, C2C12 cells incubated in DM for 3 days were separated into myotubes 
and reserve cells, as in Fig.3-1, lyzed, and immunoblotted with anti-Dll1 antibody. Arrows 
indicate Dll1FL, Dll1TMIC, and Dll1IC, respectively; asterisk marks a non-specific band (left 
panels). The position of Dll1FL corresponds to the position of the radioactive 90-kDa Dll1FL band 
detected in the immunoprecipitate from [35S]-labeled C2C12 cells (right, top). Dll1TMIC and 
Dll1IC contain ~10 times less cysteine and methionine residues than the full-length Dll1 and give 
weak signals in autoradiograms. The identities of Dll1TMIC and Dll1IC are confirmed by the 
relative increase in the abundance of Dll1TMIC and decrease in the abundance of Dll1IC after 
treatment of C2C12 cells with DAPT (right, bottom). 
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Figure 3-5. Soluble, catalytically-inactive extracellular domain of ADAM12 inhibits Dll1 
processing and stimulates Notch signaling in myoblasts. (A) Coomassie blue-stained SDS-
PAGE gel showing the recombinant, soluble, extracellular domain of mouse ADAM12 
containing the E349Q mutation in the catalytic site (protein X), expressed in Drosophila S2 cells 
and purified from culture medium. The molecular weight markers (kDa) are shown on the right. 
(B) Inhibition of Dll1 cleavage by protein X. Left, COS-7 cells transfected to express Dll1 were 
incubated for 24 hours in the absence or presence of 2 µM protein X. Right, Cell extracts from 
Dll1-transfected and empty vector (V)-transfected cells were analyzed by Western blotting using 
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antibody against the cytoplasmic domain of Dll1. Dll1FL and Dll1TMIC are indicated with the 
arrows, positions of the molecular weight markers are on the right. Left, The extent of Dll1 
cleavage was calculated as the ratio of band intensities of Dll1TMIC and Dll1FL (mean ± s.e.m., 
n=3). (C) The effect of protein X on Notch signaling. (a) Top, Primary myoblasts were incubated 
for 1 day in DM without protein X or with 2 µM protein X, in the absence or presence of 1 µM 
DAPT (D). The level of active Notch, NICD, was analyzed by Western blotting using an 
epitope-specific antibody, tubulin is a gel-loading control. Bottom, The amount of NICD was 
quantified by densitometry and normalized to the amount of tubulin (mean ± s.e.m., n=3). (b) 
Primary myoblasts or C2C12 cells were transfected with a CBF1-luciferase reporter and pRL-TK 
vector, 24h after transfection cells were transferred to DM (Day 0) and incubated for additional 
24h (Day 1), in the absence (gray bars) or presence (black bars) of 2 µM protein X. The relative 
firefly and Renilla luciferase activities were measured using the Dual-Luciferase reporter assay. 
Fold of CBF1 activation over the level at Day 0, in the absence of protein X, was calculated. The 
data represent the means ± s.e.m. from three measurements, the experiment was repeated twice 
with similar results. 
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Figure 3-6. The effect of protein X on the myogenic progression and Pax7 expression.  (A) 
Primary myoblasts were incubated for 1 day in DM without protein X or with 2 µM protein X, in 
the absence or presence of 1 µM DAPT (D). Levels of Pax7, MyoD, myogenin, p21, and tubulin 
expression were examined by Western blotting, band intensities were quantified by densitometry 
and are plotted on the right. Data represent mean values ± s.e.m. from three different 
experiments. (B) C2C12 cells were incubated for 1 day in DM without or with 2 µM protein X, 
and the levels of Pax7, MyoD, myogenin, p21, and tubulin expression were examined as in panel 
A. (C) Left, Primary myoblasts incubated for 1 day in DM without or with 2 µM protein X were 
co-stained with rabbit anti-MyoD and mouse anti-Pax7 antibodies and with AMCA-conjugated 
anti-rabbit IgG and rhodamine Red-X-conjugated anti-mouse IgG antibodies. Two representative 
images are shown. Right, The numbers of Pax7+/MyoD+, Pax7+/MyoD-, and Pax7-/MyoD+ cells 
were counted in 15 different microscopic fields, 300-400 cells were analyzed for each 
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experimental condition (without and with protein X). The data show mean values of cells 
counted on 3 different slides, error bars represent standard error of the mean (*, p<0.05). The 
experiment was repeated twice with similar results. 
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Figure 3-7. Proposed model of modulation of Notch activity by Dll1 shedding during 
myogenic differentiation. The Notch pathway is active in proliferating Pax7+/MyoD+ cells 
derived from Pax7+ quiescent satellite cells. Upon exit from the cell cycle, Notch signaling is 
down-regulated in Pax7+/MyoD+ cells that later become Pax7-/MyoD+, progress into 
differentiation, and eventually fuse to give rise to myofibers. The level of Notch activity (shown 
as the yellow gradient) is maintained (or up-regulated) in Pax7+/MyoD- cells that replenish the 
pool of satellite cells. The balance between Pax7+/MyoD- and Pax7+/MyoD+ cells is maintained 
by Dll1 shedding by ADAM proteases in a stochastic and cell density-dependent manner. Dll1 
shedding in a pool of cells leads to ligand depletion and down-regulation of Notch signaling in 
neighboring cells, maintenance of MyoD expression, and eventually loss of Pax7 expression. 
Cells in which Dll1 cleavage takes place acquire higher level of Notch activity than their 
neighbors, leading to down-regulation of MyoD and sustained Pax7 expression. 
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CHAPTER 4 
 
TRANSCRIPTIONAL UP-REGULATION OF MnSOD BY PAX7 
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Introduction 
R
C
T
M
eactive oxygen species (ROS) are highly reactive oxygen ions, free radicals and peroxides 
which damage cellular constituents, including proteins, lipids, DNA and RNA. Cells have 
developed defense system against ROS damage through enzymes such as superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase (GPx). Superoxide dismutase catalyzes the 
dismutation of superoxide. Three mammalian superoxide dismutases have been discovered. 
CuZn-SOD (SOD1) is a homodimer that bears copper and zinc, and is found in the cytoplasm. 
EC-SOD (SOD3), a copper and zinc-containing tetramer, functions in the extracellular space 
(Zelco et al., 2002). Manganese superoxide dismutase (MnSOD), also known as superoxide 
dismutase-2 (SOD2), is a mitochondrial enzyme that represents a major cellular defense system 
against superoxide free radicals (Faraci et al., 2004). MnSOD forms homotetramers and binds 
one manganese ion per subunit. 
ertain properties of skeletal muscle, including high metabolic activity and high level of 
heme-containing proteins, render it particularly susceptible to injury from reactive oxygen 
species (Chan et al., 1994). Together with other antioxidant enzymes, including CuZn-SOD, 
glutathione peroxidase and catalase, mRNA level and enzyme activity of MnSOD decrease as 
muscle differentiation occurs. This correlates with the fact that differentiated myotubes are more 
susceptible to oxidative injury compared with undifferentiated myoblasts (Alexa et al., 1999). 
he Human MnSOD gene has been shown to be induced by TPA (a phorbol ester, 12-O-
tetradecanoylphorbol-13-acetate) via activation of a CREB-1/ATF-1-like factor (Kim et al., 
1999). Cytokines also induce MnSOD expression in insulin-producing cells. Two interleukin-1β-
responsive elements have been identified, with one located in the promoter region and the other 
one located in the second intron of the MnSOD gene. NF-κB is required for this process, as it 
cooperates with CCAAT/enhancer-binding proteins in the promoter region and with octamer and 
Ets factors in the intronic region (Darville et al., 2000). Vascular Endothelial Growth Factor 
(VEGF) also activates MnSOD transcription through NF-κB, and the activation is dependent on 
a second intronic NF-κB consensus motif (Abid et al., 2004). 
nSOD is a transcriptional target of the FOXO family of forkhead transcription factors 
(Kops et al., 2002; Essers et al., 2004; Adachi et al., 2007). Forkhead transcription factors are 
characterized by the presence of a highly conserved DNA binding domain, with a structure of 
three α-helices and two large loops, often referred to as winged-helix motif (Weigel et al., 1990). 
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FOXO (Forkhead box, class O) factors are the only known forkhead proteins regulated by the 
PKB/Akt pathway. Protein kinase B (PKB/Akt) is a negative regulator of FOXOs. In response to 
insulin, FOXO proteins are phosphorylated by PKB/Akt. This results in their nuclear exclusion 
(Brunet et al., 1999; Kops et al., 1999) and subsequent proteasomal degradation (Matsuzaki et 
al., 2003). In proliferating cells, active PKB/Akt drives cellular proliferation and protects cells 
from apoptosis (Coffer et al., 1998; Datta et al., 1999). In quiescent cells, when PKB/Akt is 
silent, FOXO family members play an important role in controling quiescence, oxidative stress 
and apoptosis (Burgering et al., 2003). The mammalian FOXO family of forkhead transcription 
factors includes FOXO1 (FKHR), FOXO3a (FKHRL1) and FOXO4 (AFX).  
In
P
 human colon carcinoma cells, when the protective mechanism of PKB-mediated 
signaling is absent, active FOXO3a protects quiescent cells from oxidative stress by 
transcriptional up-regulation of MnSOD. This results in protection of cells from reactive oxygen 
species and antagonizes apoptosis caused by glucose deprivation (Cops et al., 2002). In C. 
elegans, the absence of PKB signaling activates the FOXO homologue DAF-16 and generates a 
phenotype characterized by increased resistance to oxidative stress (Ogg et al., 1997; Paradis et 
al., 1998; Honda et al., 1999). DAF16, AFX, FKHR and FKHRL1 share a common consensus 
binding sequence of 8bp (5`-TTGTTTAC-3`) called DBE. The transcriptional activation is 
controlled in a dose-dependent manner by FOXO expression and is sensitive to the number of 
DBE elements (Furuyama et al., 2000). Two FOXO-binding elements (DBE) have been 
identified in the human MnSOD promoter region: one inverse DBE at position -1249 to -1241 
(GTAAACAA; DBE1) and one suboptimal DBE at position -997 to -989 (TTGTTTAA; DBE2). 
It has been shown that only DBE1 is required for activation of MnSOD through FOXO3a (Cops 
et al., 2002). 
ax proteins are a family of transcription factors characterized by a paired domain. Pax 
proteins play critical roles in formation of tissues and organs during embryogenesis (Tremblay 
and Gruss, 1994). Pax7 and Pax3 are two closely related family members that mark myogenic 
progenitor cells and regulate their entry into myogenic differentiation (Relaix et al., 2005). Pax7 
and Pax3 share a common structure containing a paired domain, an octapeptide and a 
homeodomain. Pax7 is required for maintenance of the satellite cell pool in skeletal muscle and 
to protect satellite cells from apoptosis. The anti-apoptotic function of Pax7 cannot be replaced 
by Pax3 (Relaix et al., 2006). 
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It
 has been shown that Pax7 interacts with the histone methyltransferase (HMT) complex 
Wdr5-Ash2L-MLL2 and directs the methylation of histone H3 lysine4 (H3K4). Methylation of 
H3K4 causes chromatin to become more permissive for transcription. As a result, Pax7 
stimulates transcriptional activation of target genes and regulates the myogenic development 
program. The expression of Myf5, a myogenic regulatory factor, is increased by this mechanism 
(McKinnell et al., 2008). By analyzing target genes identified using Pax7-chromatin 
immunoprecipitation (ChIP), a core motif GTCAC was recognized as the Pax7 consensus 
binding site. Pax7 directly occupies this site within target genes. The target genes with one or 
more such sites include the transcription factors Gbx1 and Eya4, the neurogenic cytokine 
receptor CntfR, the neuronal potassium channel Kcnk2, and the signal transduction kinase 
Camk1d in vivo and in cultured cells (White et al., 2008). 
ax7 is essential for maintenance of muscle satellite cells. In skeletal muscle of Pax7 
knockout mice, satellite cells are present, but exist in reduced numbers as the mice mature 
(Oustanina et al., 2004). This is due to satellite cell death. While MnSOD knockout mice exhibit 
neonatal lethality, heterozygous MnSOD knockouts have normal life-span, but show increased 
oxidative damage and incidence of apoptosis (Van et al., 2001). 
ax7 is essential for protecting muscle satellite cells from apoptosis, but the mechanism of 
its action is not clear. As both Pax7 and MnSOD protect quiescent cells from apoptosis, we 
asked whether Pax7 exerts its anti-apoptotic function through up-regulation of MnSOD. In this 
study, we show that in C2C12 cells, exogenous expression of Pax7 up-regulates MnSOD 
promoter in a dose-dependent manner. In COS7 cells, transfection of Pax7 increases MnSOD 
protein expression. Up-regulation of MnSOD promoter by Pax7 is not mediated by FOXO 
family members. Two Pax7 consensus binding sites are found in the MnSOD promoter 
sequence. However, activation of the MnSOD promoter by Pax7 does not occur through direct 
binding to these sites. 
 
Results 
 has been shown that Pax7 is essential for protecting muscle satellite cells from apoptosis 
(Relaix et al., 2006). MnSOD knockout mice show increased oxidative damage and incidence of 
apoptosis (Van et al., 2001). We examined the effect of exogenous Pax7 expression on the 
MnSOD promoter. C2C12 myogenic cells were co-transfected with luciferase reporter under the 
 85
control of MnSOD promoter, pRL-TK vector and mouse Pax7 expression vector or empty 
vector. pRL-TK vector, which expresses Renilla luciferase, was used as an internal control for 
transfection efficiency. 24 hours after transfection, MnSOD promoter activity was measured as a 
ratio of firefly luciferase activity to Renilla luciferase activity. With the increased expression of 
Pax7 protein, MnSOD promoter activity was induced in a dose-dependent manner (Fig.4-1AB). 
The increased expression of Pax7 was confirmed by Western blotting using the same cell lysates 
as used for measurement of luciferase activity (Fig.4-1C). These results show that Pax7 activates 
MnSOD at the transcriptional level in a dose-dependent manner. 
T
It
o examine the up-regulation of MnSOD protein by Pax7, we used COS7 cells, which are 
characterized by higher transfection efficiency than C2C12 cells. It has been shown that MnSOD 
is a transcriptional target of forkhead FOXO proteins (Kops et al., 2002; Essers et al., 2004; 
Adachi et al., 2007). FOXO proteins are phosphorylated and excluded from nucleus in response 
to insulin. Upon serum withdrawal, FOXO proteins are de-phosphorylated, translocated into 
nucleus and become active transcription factors (Brunet et al., 1999; Kops et al., 1999). We 
reasoned that serum free condition would help activate MnSOD if FOXO proteins are involved. 
On the other hand, if FOXO proteins are not mediating Pax7 up-regulation of MnSOD, insulin 
should decrease the background MnSOD protein level and make the specific up-regulation by 
Pax7 more prominent. Here, we incubated COS7 cells under three different conditions for 24 
hours after transfection with Pax7 expression vector or empty vector. Cells were incubated in 
normal growth medium, serum free medium and serum free medium with 100 nM insulin for an 
additional 24 hours. Under all conditions, the endogenous MnSOD proteins were increased after 
exogenous expression of Pax7, with about 10% increase in growth medium, about 30% increase 
in serum free medium and about 50% increase in serum free medium with insulin, respectively 
(Fig.4-2AB). Together, these results show that over-expression of Pax7 up-regulates MnSOD 
protein expression. 
 has been shown that FOXO family members share a common 8bp consensus binding 
sequence, called DBE (Furuyama et al., 2000). There are two DBE elements in human MnSOD 
promoter, one inverse DBE at position -1249 to -1241 (DBE1), and one suboptimal DBE at 
position -997 to -989 (DBE2) (Fig.4-3A). A single C to G mutation in the AAACAA sequence of 
DBE1 completely abolished FOXO3a-mediated expression of MnSOD, while a single G to C 
substitution in the TTGTTT sequence of DBE2 does not affect FOXO3a-mediated activation in 
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human colon carcinoma cells (Cops et al., 2002). Here, we generated the C to G point mutation 
in DBE1 and the G to C point mutation in DBE2 sequences of MnSOD promoter respectively 
and generated the double DBE mutant with both point mutations (Fig.4-3A). After co-
transfection of these mutants with Pax7 expression vector into C2C12 or COS7 cells, Pax7-
mediated up-regulation of MnSOD promoter was not affected by the point mutations (Fig.4-
3BC). These results suggest that the transcriptional up-regulation of MnSOD by Pax7 does not 
involve FOXO proteins. 
A
In
 Pax7 consensus binding site, GTCAC, has been recently identified by analysis of target 
genes recognized by Pax7-chromatin immunoprecipitation (White et al., 2008). Our 3340-base 
pair MnSOD promoter luciferase construct contains the MnSOD promoter fragment and part of 
intron 1. After analysis of the sequence, we identified one Pax7 consensus binding site at 
position +118 to +123 within intron 1 and one inverse Pax7 consensus binding site at position -
1854 to -1849 within the promoter region (Fig.4-4A). As there is no literature report indicating 
which nucleotide is essential for Pax7 binding, we decided to delete all five nucleotides within 
each site. We generated a single deletion mutant with the Pax7 binding site in intron 1 deleted 
and a double deletion mutant with the inverse Pax7 binding site in promoter region deleted in 
addition to the first deletion (Fig.4-4A). After co-transfection of deletion mutants with Pax7 
expression vector, luciferase reporter assay suggested that the mutant promoter constructs could 
be activated by Pax7 expression to the same extent as the wild type promoter construct in both 
C2C12 and COS7 cells (Fig.4-4BC). Together, these results show that the transcriptional up-
regulation of MnSOD by Pax7 does not occur through direct binding of Pax7 to the MnSOD 
promoter. 
 
Discussion 
 muscle satellite cells, Pax7 plays a critical role in cell survival, an essential function that 
cannot be replaced by Pax3 (Relaix et al., 2006). As a result, in Pax7 knockout mice, muscle 
satellite cells are rapidly lost due to apoptosis as the mice mature (Oustanina et al., 2004). So far, 
the mechanism of how Pax7 performs its anti-apoptotic function is not known. MnSOD 
heterozygous knockout mice have increased oxidative damage and incidence of apoptosis (Van 
et al., 2001). Here, our study suggests that Pax7 increases MnSOD expression at the 
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transcriptional level. This provides an insight into the mechanism of Pax7-mediated muscle 
satellite cell survival. 
M
 members play an important role in control of quiescence, oxidative stress 
and apo
nSOD is a mitochondrial enzyme that represents a major cellular defense system against 
superoxide free radicals (Faraci et al., 2004). Both C2C12 and COS7 cell lines that we tested 
have high levels of the endogenous MnSOD protein. NF-κB and FOXO proteins are well-known 
positive regulators of MnSOD transcription (Darville et al., 2000; Abid et al., 2004; Kops et al., 
2002; Essers et al., 2004; Adachi et al., 2007). Our study shows that exogenous Pax7 activates 
MnSOD at the transcriptional level and leads to increased MnSOD protein expression (Fig.4-1 
and Fig.4-2). To determine whether Pax7 is indispensable for MnSOD expression, comparing the 
MnSOD protein levels in myoblasts of Pax7-/- mice with their wild-type control, or decreasing 
the endogenous Pax7 expression by siRNA would provide more accurate answer. Since Pax7-
deficient mice do not exhibit neonatal lethality as MnSOD homozygous knockouts do, Pax7 may 
not be essential for the maintenance of MnSOD expression. However, this does not exclude the 
possibility that MnSOD is necessary for mediating the anti-apoptotic function of Pax7 in 
quiescent muscle satellite cells. One approach to determine the necessity of MnSOD should be to 
transfect MnSOD-/- myoblasts with Pax7. If Pax7 loses its anti-apoptotic function in the absence 
of MnSOD, then one can conclude that MnSOD is a critical mediator of cell survival for Pax7. 
FOXO family
ptosis (Burgering et al., 2003). MnSOD is a transcription target of FOXO proteins (Kops 
et al., 2002; Essers et al., 2004; Adachi et al., 2007). FOXO proteins, MnSOD and Pax7 all have 
essential functions in protecting quiescent cells from apoptosis. We examined the involvement of 
FOXO proteins in Pax7-mediated up-regulation of MnSOD transcription. Although DBE1 has 
been shown to be important for FOXO3a mediated activation of MnSOD expression (Kops et al., 
2002), both DBEs proved to be non-essential for increased MnSOD promoter activity by Pax7 
(Fig.4-3). Since DBE is a common consensus binding sequence shared by DAF16, AFX, FKHR 
and FKHRL1 (Furuyama et al., 2000), our findings suggest that the activation of MnSOD 
transcription by Pax7 is independent of the activation of MnSOD transcription by FOXO 
proteins. The increased MnSOD protein after Pax7 transfection upon addition of insulin, which 
favors the nuclear exclusion and inactivation of FOXO proteins, also suggests that FOXO 
proteins are not involed (Fig.4-2). 
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RP
p
ecent studies shed insight into the mechanism of Pax7 function as a transcriptional 
activator. It has been shown that Pax7 interacts with histone methyltransferase (HMT) complex 
Wdr5-Ash2L-MLL2 and directs the methylation of histone H3 lysine4. Binding of HMT-Pax7 to 
Myf5, which is a myogenic regulatory factor, resulted in its increased expression (Mckinnell et 
al., 2008). This model involves chromatin modification, and appears to be a rather broad 
spectrum activation. It has been shown that by this mechanism Pax7 increases expression of a 
number of genes. However, this mechanism is less important in our experiments, as the 
transfected MnSOD promoter construct we used is independent of chromatin regulation. By 
analysis of target genes identified using Pax7-chromatin immunoprecipitation (ChIP), a core 
motif GTCAC is recognized as the Pax7 consensus binding site. Pax7 directly occupies this site 
within target genes (White et al., 2008). We identified two Pax7 consensus binding sites in the 
MnSOD promoter and have those sites deleted in our mutant constructs. Our results show that 
the identified Pax7 binding sites are not involved in MnSOD promoter activation (Fig.4-4). This 
indicates that activation of MnSOD by Pax7 may be indirect and may require other transcription 
factors. 
ax7 activates MnSOD at the transcriptional level. Our study provides a possible answer to 
the question how Pax7 mediates cell survival in muscle satellite cells. We have excluded the 
involvement of FOXO proteins and the direct binding to Pax7 consensus binding sites in the 
MnSOD promoter. The mechanism by which Pax7 activates MnSOD promoter remains to be 
examined. The co-factors involved in the activation and the precise sites in the MnSOD promoter 
await determination. 
 
Materials and Methods 
Expression constructs 
MnSOD3340 luciferase reporter construct was a gift of Dr. Boon Chock, NHLBI. 
pMnSOD3340 DBE1 mutant, DBE2 mutant and double mutant were generated using 
QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) according to the 
manufacture’s protocol with primers 5’-CTGACGTCTGTAAAGAAGCCCAGCCCTTC-3’ and 
5’-CACACCATTCAGGATTGTTCTTTAACTGTTGAGAGAGCA-3’, respectively. 
pMnSOD3340 Pax7 binding site deletion mutant and Pax7 binding site together with inverse 
Pax7 binding site double deletion mutant were created with primers 5’-
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GAAAGGGGACCCGGGCCCCAAGGGGC-3’ and 5’-
TCTCATAGCTAGTGCCCTTAAAACTGCAGTACCTCC-3’, respectively. 
M
C
T
2
C
ouse Pax7-pcDNA3 expression vector was provided by Dr. Micheal Rudnicki, 
University of Ottawa. pcDNA3 empty vector was generated by deletion of the Pax7 cDNA 
between two HindIII sites. 
 
Cells 
2C12 and COS7 cells were obtained from American Tissue Culture Collection. C2C12 
and COS-7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) at 37˚C in presence of 5% CO2 under a humidified 
atmosphere. 
 
Plasmid transfection 
ransient transfections were performed using Fugene 6 transfection reagent (Roche 
Applied Science) according to the manufacturer’s protocol, one day after plating cells. 
 
Cell treatments 
4 hours after transfection, COS7 cells were incubated in normal growth medium (GM), 
serum free medium (SFM) or SFM with 100 nM insulin for additional 24 hours before samples 
were collected for Western blotting. 
 
Western blotting 
ells were incubated in extraction buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-sulfonyl 
fluoride hydrochloride (AEBSF), 5 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml pepstatin A, 10 
mM 1,10-phenanthroline) for 15 min at 4˚C. Cell extracts were centrifuged at 21,000xg for 15 
min. Supernatants were resolved by SDS-PAGE and transferred to a nitrocellulose membrane. 
The membranes were blocked in DPBS containing 3% (w/v) dry milk and 0.3% (v/v) Tween 20, 
then incubated with primary antibodies in blocking buffer, followed by incubation with 
horseradish peroxidase-labeled secondary antibodies and detection using the WestPico 
chemiluminescence kit (Pierce). The following primary antibodies were used: mouse anti-Pax7 
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(ascites, Developmental Studies Hybridoma Bank, 1:4000), rabbit anti-MnSOD (Stressgen, 
1:10,000), mouse anti-α-tubulin (Sigma, 1:100,000). Secondary antibodies were horseradish 
peroxidase-conjugated anti-rabbit or anti-mouse IgG. 
 
Luciferase reporter assay 
Cells in 6-well plates were transfected at 60% confluency with 0.5 µg pMnSOD3340 
firefly luciferase reporter or firefly luciferase reporter with MnSOD promoter containing 
mutations, 0.05 µg Renilla luciferase (pRL-TK) vector, together with Pax7 expression vector or 
control empty vector. 24 hours after transfection, firefly and Renilla luciferase activities were 
measured using Dual-Luciferase reporter assay system (Promega). The activity of Renilla 
luciferase was used as an internal control for transfection efficiency. 
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Figure 4-1. MnSOD promoter activity is increased by Pax7 transfection in a dose-dependent 
manner. C2C12 cells were co-transfected with MnSOD firefly luciferase reporter, pRL-TK 
vector and mouse Pax7 expression vector or empty vector. (A) 24 h after transfection, the 
relative firefly and Renilla luciferase activities were measured using the Dual-Luciferase reporter 
assay. The data represent the mean ± s.e.m. from two measurements. The experiment was 
repeated twice with similar results. (B) The ratios of the relative luciferase activities from Pax7-
transfected cells to the empty vector-transfected cells were calculated. (C) Western blotting with 
anti-Pax7 monoclonal antibody was performed to show the increased expression of Pax7 protein 
in C2C12 cells. 
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Figure 4-2. MnSOD protein expression is up-regulated by Pax7 transfection. (A) COS7 cells 
were transfected with either Pax7 expression vector or empty vector as control. 24 h after 
transfection, cells were incubated in growth medium (GM), in serum free medium (SFM) or in 
SFM with 100 nM insulin for additional 24 h. The expression levels of Pax7 and MnSOD 
proteins were examined by Western blotting, and α-tubulin was used as loading control. (B) 
Band intensities of MnSOD protein were quantified by densitometry, and normalized to the 
amount of tubulin. Data represent the mean values ± s.e.m. from three different experiments. 
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Figure 4-3. Up-regulation of the MnSOD promoter by Pax7 does not involve FOXO 
proteins. (A) The linearized MnSOD promoter containing two consensus FOXO proteins 
binding (DBE) sites (wt), carrying a point mutation in DBE1 site (DBE1m), carrying a point 
mutation in DBE2 site (DBE2m) and carrying both point mutations in DBE1 and DBE2 sites 
(DBEdbm). C2C12 cells (B) or COS7 cells (C) were co-transfected with luciferase reporter 
under the control of MnSOD promoter or MnSOD promoter mutants, pRL-TK vector and mouse 
Pax7 expression vector or empty vector. 24 h after transfection, the relative firefly and Renilla 
luciferase activities were measured using the Dual-Luciferase reporter assay. The data represent 
the means ± s.e.m. from two measurements. The experiment was repeated twice with similar 
results.  
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Figure 4-4. Up-regulation of MnSOD promoter by Pax7 is not through consensus Pax7 
binding sites. (A) The linearized MnSOD promoter fragment containing two consensus Pax7 
binding sites (wt), carrying a single Pax7 binding site deletion mutation (delsgm), and carrying 
double Pax7 binding sites deletion mutations (deldbm). C2C12 cells (B) or COS7 cells (C) were 
co-transfected with luciferase reporter under the control of MnSOD promoter or MnSOD 
promoter mutants, pRL-TK vector and mouse Pax7 expression vector or empty vector. 24 h after 
transfection, the relative firefly and Renilla luciferase activities were measured using the Dual-
Luciferase reporter assay. The data represent the means ± s.e.m. from two measurements. The 
experiment was repeated twice with similar results. 
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CHAPTER 5 
 
DECREASED EXPRESSION OF PAX7 PROTEIN BY RHABDOMYOSARCOMA 
INITIATOR PAX7-FKHR FUSION PROTEIN 
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Introduction 
R
T
P
habdomyosarcoma (RMS) is a highly malignant soft tissue tumor found in children and 
young adults. Its two main subtypes are embryonal rhabdomyosarcoma (ERM) and alveolar 
rhabdomyosarcoma (ARM). ARM is the more aggressive subtype (Tsokos et al., 1992). RMS 
cells express a number of skeletal muscle markers, such as desmin, sarcomeric actin, sarcomeric 
myosin heavy chain and MyoD, which suggests its myogenic origin (Merlino and Helman, 
1999). Embryonal RMS is characterized by loss of heterozygosity on the short arm of 
chromosome 11 (Loh et al., 1992). Approximately 70% of alveolar RMS has one of two specific 
chromosomal translocations, which fuse the Pax3 or Pax7 gene on chromosome 1 or 2 to the 
FKHR gene on chromosome 13 (Turc-Carel et al., 1986; Douglass et al., 1987; Wang-Wuu et al., 
1988). Among patients with the chromosomal translocation-positive ARMs, the Pax7-FKHR 
fusion protein is present in ~20% cases. 
he chromosomal translocations break within intron 7 of paired box transcription factor 
Pax3 or Pax7 and within intron 1 of the forkhead transcription factor FKHR. The product 
connects 5’-end of Pax3 or Pax7 to the 3’-end of FKHR, and generates a fusion protein with 
Pax3 or Pax7 DNA binding domain and the FKHR transcription activation domain (Fig.1-3) 
(Barr et al., 1993; Galili et al., 1993; Shapiro et al., 1993; Davis et al., 1994). The fusion proteins 
are more potent transcriptional activators than wild-type Pax3/7 or FKHR due to several reasons. 
First, the FKHR transactivation domain is insensitive to the inhibitory effects of the N-terminal 
Pax3 or Pax7 domains (Bennicelli et al., 1995). Second, unlike the wild-type FKHR, the 
transcriptional activity and the nuclear localization of fusion proteins are not regulated by Akt 
phosphorylation (Peso et al., 1999). Third, the fusion genes are over-expressed in ARM. The 
Pax7-FKHR over-expression is associated with gene amplification. The Pax3-FKHR over-
expression results from copy number-independent fusion gene transcription (Davis and Barr, 
1997). Thus, Pax3-FKHR and Pax7-FKHR use “gain of function” mechanism relative to the 
wild-type Pax3 and Pax7 proteins in ARM. 
ax3 and Pax7 are closely related Pax family members that play essential roles in neural 
and muscle development. They are characterized by an N-terminal DNA binding paired box 
domain, a short conserved octapeptide motif and a complete homeobox. They also have a 
proline-, serine- and threonine-rich C-terminal transactivation domain (Jun and Desplan, 1996; 
Seo et al., 1998). Pax3 and Pax7 partially overlap in their expression during development. They 
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both have essential functions in the development of embryonic neural cells (Kalcheim and Le 
Douarin, 1986). Pax3 and Pax7 are also crucial for embryonic development of skeletal muscle 
(Kassar-Duchossoy et al., 2005; Relaix et al. 2005). Pax7 is indispensible in the maintenance of 
muscle satellite cells (Seale et al., 2000; Oustanina et al., 2004; Kuang et al., 2006). The number 
of satellite cells declines strongly during postnatal development in Pax7-null mice. This is a 
result of the anti-apoptotic role played by Pax7, which cannot be compensated by Pax3. Pax7 
also helps to maintain the quiescent state of satellite cells by delaying the onset of myogenic 
differentiation (Zammit et al., 2006). 
U
T
T
biquitination is a post-translational modification that controls protein stability. It has been 
revealed that Pax3 is regulated by mono-ubiquitination and proteasomal degradation. The amino 
acid lysine 475 at the C-terminal region of Pax3 is responsible for the susceptibility to mono-
ubiquitination. The corresponding residue in Pax7 is an alanine (Ala486), which is not a target 
for ubiquitination. As a result, Pax7 is not susceptible to proteasomal degradation (Boutet et al., 
2007). 
he Pax7 gene consists of nine exons. Exons 2, 3 and 4 encode the paired domain. The 
homeodomain is encoded by exons 5 and 6. The transactivation domain is encoded by exons 6, 7 
and 8 (Vorobyov et al., 1997; Barr et al., 1999). As a result of alternative splicing which occurs 
at the intron 2/exon 3 junction and the intron 3/exon 4 junction, there are four alternative Pax7 
transcripts with the inclusion or exclusion of a tri-nucleotide, CAG, and a hexa-nucleotide, 
GTTTAG, respectively. This results in the inclusion or exclusion of a glutamine (Q) and a 
glycine-leucine dipeptide (GL) in four Pax7 isoforms (Q+GL+, Q+GL-, Q-GL+, Q-GL-)(Ziman 
and Kay, 1998). The isoforms contain distinct tertiary structures and have different DNA binding 
affinities and specificities. Corresponding to the wild-type Pax7 isoforms, there is a consistent 
pattern of co-expression of Pax7-FKHR isoforms in ARM tumors. The DNA binding ability and 
transcriptional activity of these Pax7-FKHR isoforms also vary (Du et al., 2005). 
he chromosomal translocation occurs in one set of the chromosomes, with the other set 
expressing the wild-type Pax3 or Pax7 and FKHR proteins. The wild-type Pax3 and Pax7 
proteins share the same DNA binding domains with the oncogenic Pax3-FKHR and Pax7-FKHR 
fusion proteins, and may compete with each other for DNA binding sites and protein 
interactions. Thus, the oncoproteins may need to down-regulate the wild-type proteins in order to 
circumvent the interferences. Studies of RMS tumor samples and RMS cell lines reveal that 
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wild-type Pax3 is up-regulated in both ERM and ARM. Its up-regulation is independent of 
fusion genes (Barr et al., 1999; Tiffin et al., 2003). While elevated wild-type Pax7 expression is 
also observed in ERM (Bernasconi et al., 1996; Barr et al., 1999) and in fusion negative ARM 
(Tiffin et al., 2003), Pax7 expression is reduced in primary ARM tumors with Pax-FKHR fusion 
genes (Tiffin et al., 2003), and in Pax3-FKHR or Pax7-FKHR expressing ERM cell lines 
(Tomescu et al., 2004). However, the molecular mechanism of how fusion proteins down-
regulate the wild-type Pax7 is not clear. 
In
It
 this study, we show that co-transfection with Pax7-FKHR fusion protein decreases the 
level of wild-type Pax7 protein in the presence or absence of a proteasomal inhibitor. In a human 
HEK293 cell line stably expressing exogenous Pax7 protein under the control of SV40 promoter, 
although Pax7 protein was decreased in a dose-dependent manner, Pax7 mRNA level was not 
affected by Pax7-FKHR transfection. MicroRNA microarray analysis revealed that more than 
twenty miRNAs were significantly up-regulated upon expression of Pax7-FKHR fusion protein. 
However, none of these up-regulated miRNAs targeted the short fragment of human Pax7 3’-
UTR present in our vector. 
 
Results 
 has been shown that Pax7 expression is reduced in Pax-FKHR fusion positive primary 
ARM tumors (Tiffin et al., 2003), and in Pax3-FKHR or Pax7-FKHR expressing ERM cell lines 
(Tomescu et al., 2004). To examine the direct effect of Pax7-FKHR fusion protein on Pax7 
expression, we co-transfected C2C12 myogenic cells with human Pax7 expression vector and 
different doses of human Pax7-FKHR expression vector. On Western blots, both Pax7 (57kDa) 
and Pax7-FKHR (94kDa) can be detected by an antibody recognizing the N-terminal consensus 
sequence of Pax proteins. The exogenous Pax7 protein was decreased upon co-expression of the 
fusion protein (Fig.5-1A). Pax7-FKHR may form heterodimers with the wild-type Pax7 and 
affect Pax7 protein stability. To determine whether the decreased Pax7 was due to protein 
degradation, we treated C2C12 cells with a proteasomal inhibitor, MG132, 24 hours after 
transfection. In the presence of a proteasomal inhibitor, Pax7-FKHR fusion protein was 
stabilized and a more pronounced decrease of wild-type Pax7 was observed with the fusion 
protein co-transfection (Fig.5-1B). This result is consistent with the observations from a study on 
the regulation of Pax3 proteasomal degradation (Boutet et al., 2007). The amino acid lysine 475 
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at the C-terminal region of Pax3 is responsible for its susceptibility to mono-ubiquitination and 
proteasomal degradation. The corresponding residue in Pax7 is an alanine (Ala486), which is not 
a target for ubiquitination. As a result, Pax7 is not susceptible to proteasomal degradation. 
Furthermore, within the Pax7-FKHR fusion protein, the C-terminal part containing the Ala486 is 
replaced by the C-terminal domain of FKHR protein, which may contain an ubiquitination and 
proteasomal degradation target site. To obtain a higher expression level of Pax7 and Pax7-FKHR 
proteins, we transfected COS7 cells with a fixed dose of human Pax7 expression vector and 
increased doses of human Pax7-FKHR expression vector. COS7 cells were treated with MG132, 
24 hours after transfection. A dose-dependent decrease of the wild-type Pax7 protein was 
observed with the increasing levels of the fusion protein (Fig.5-1C). Together, these co-
transfection results show that the wild-type Pax7 protein is decreased by co-expression of Pax7-
FKHR fusion protein. The decreased Pax7 protein level is independent of proteasomal 
degradation. 
T
T
ransient transfection may cause the initial unevenness in Pax7 expression level, which 
interferes with the effect induced by Pax7-FKHR. We next generated HEK293 cells stably 
expressing exogenous human Pax7. HEK293 cell line is a human cell line which does not have 
endogenous Pax7 expression. After transfection with human Pax7 expression vector or empty 
vector, HEK293 cells were selected for two weeks in the presence of G418. As determined by 
immunofluorescence microscopy, approximately 70% of HEK293 cells were Pax7-positive after 
selection (Fig.5-2A). Pax7-expressing HEK293 cells were transfected with Pax7-FKHR fusion 
protein, and treated with MG132, 24 hours after transfection. With the increasing amounts of the 
fusion protein, Pax7 protein level was reduced to ~70%, ~40% and ~30%, respectively, as 
compared to the empty vector transfected HEK293-Pax7 cells (Fig.5-2B). These results indicate 
that Pax7 protein is decreased by Pax7-FKHR fusion protein expression in a dose-dependent 
manner. 
he exogenous Pax7 introduced to HEK293 cells is under the control of a constitutively 
active SV-40 promoter, which makes the expression of Pax7 independent of its natural promoter 
regulation. After excluding the involvement of proteasomal degradation, we next asked whether 
the mRNA level of Pax7 is affected by Pax7-FKHR fusion protein expression. Similar to the 
previous experiment, HEK293 stably transfected cells were treated with MG132, 24 hours after 
transfection of the fusion protein. After total RNA extraction and reverse transcription, we used a 
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PCR primer set detecting only the wild-type Pax7, not Pax7-FKHR fusion protein. PCR 
amplification of Pax7 occurred only in Pax7-expressing HEK293 cells, not in empty vector 
transfected cells without or with Pax7-FKHR transfection (Fig.5-3A). Semi-quantitative PCR 
results suggested that in HEK293-Pax7 cells, the mRNA level of Pax7 was not changed by 
transfection and increasing expression of Pax7-FKHR (Fig.5-3A). β-actin was used as an internal 
control for total RNA amount. The unaltered Pax7 mRNA level upon the fusion protein 
transfection was confirmed by real time PCR experiment using the same cDNA preparations 
(Fig.5-3B). Taken together, these results suggest that although the protein level of Pax7 was 
decreased markedly, the mRNA level of Pax7 is not changed by Pax7-FKHR fusion protein 
expression. 
T
T
o further compare Pax7 mRNA stability with and without fusion protein transfection, we 
treated HEK293-Pax7 cells with actinomycin D to inhibit transcription and prevent the synthesis 
of new mRNA. HEK293 cells stably expressing Pax7 were transfected with either empty vector 
or Pax7-FKHR expression vector. 24 hours after transfection, cells were treated with MG132 for 
10 hours, followed by treatment with actinomycin D in the presence of MG132. Total mRNA 
from vector transfected and Pax7-FKHR transfected cells was collected 0, 1, 2, 4 and 6 hours 
after adding actinomycin D. Pax7 mRNA levels were determined by semi-quantitative PCR. As 
expected, Pax7 mRNA level was decreased in both vector- and fusion protein-transfected cells 
after addition of actinomycin D. Importantly, the decay rate of Pax7 mRNA in Pax7-FKHR 
fusion protein-transfected cells was similar to the decay rate in empty vector-transfected cells, 
with a rapid reduction to ~60% after 1 hour treatment and then more modest reduction to 40-50% 
during the 6 hour-incubation (Fig.5-4). This result indicates that Pax7 mRNA stability is not 
affected by the fusion protein transfection, and confirms that the decreased Pax7 protein is not 
due to the decrease in mRNA level. 
he deceased protein expression without changes in mRNA level suggests a specific Pax7-
FKHR-induced inhibition of Pax7 mRNA translation. MicroRNAs (miRNAs) can block the 
translational machinery and prevent protein translation without causing mRNA degradation. 
Mammalian microRNAs frequently target the 3’-UTR and function as negative regulators of 
gene expression. The human Pax7 expression construct, which we introduced to HEK293 cells, 
includes a short fragment of 3’-UTR containing several potential miRNA target sites. These 
potential miRNAs include hsa-miR-19b-2*, hsa-miR-19b-2* and hsa-miR-665 from the Sanger 
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Institue Database (microrna.sanger.ac.uk), and hsa-miR-575 from the TargetScan Database 
(www.targetscan.org). HEK293 cells were transiently transfected with empty vector, Pax7 
expression vector, or Pax7-FKHR expression vector. 24 hours after transfection, cells were 
treated with MG132 for 10 hours and total RNA samples were collected. MicroRNA microarray 
analysis was performed by LC Sciences (Houston, TX). After in-depth data analysis, the relative 
expressions for the microRNAs that changed significantly (ANOVA, p-value < 0.01) were sorted 
with a hierarchical clustering analysis (Fig.5-5). Although more than twenty miRNAs were 
significantly up-regulated in fusion-protein transfected cells, compared to empty vector- or Pax7-
transfected cells, none of predicted miRNAs for Pax7 3’-UTR were included in the list. 
 
Discussion 
A
It
pproximately 70% of alveolar RMS has one of the two specific chromosomal 
translocations on chromosome 1 or 2 with chromosome 13, which generates oncogenic fusion 
proteins Pax3-FKHR or Pax7-FKHR, respectively (Barr et al., 1993; Galili et al., 1993; Shapiro 
et al., 1993; Davis et al., 1994). The chromosomal translocation occurs in one set of the 
chromosomes, with the other set expressing wild-type Pax3 or Pax7 and FKHR proteins. The 
wild-type proteins are presumably able to perform their normal functions. The wild-type Pax3 
and Pax7 can potentially compete for binding sites with the fusion proteins as they share the 
same DNA binding domains. In fusion-positive ARM tumors, Pax3-FKHR and Pax7-FKHR are 
expressed at higher levels than the wild-type Pax3 and Pax7, respectively. Over-expression of 
Pax3-FKHR and Pax7-FKHR fusion proteins ensures a critical level of gene products for the 
oncogenic effects of these fusions (Davis and Barr, 1997). Fusion proteins could also down-
regulate the wild-type Pax3 and Pax7 to circumvent the interfering effect. Our finding of the 
down-regulation of the wild-type Pax7 protein with the Pax7-FKHR fusion protein transfection 
is consistent with previous studies, where Pax7 expression was reduced in primary ARM tumors 
with Pax-FKHR fusion genes (Tiffin et al., 2003), and in Pax3-FKHR or Pax7-FKHR expressing 
ERM cell lines (Tomescu et al., 2004). This study provides an insight into the dominant-negative 
effect of Pax7-FKHR fusion protein on the wild-type Pax7. 
 has been shown that wild-type Pax3 is up-regulated in both ERM and ARM, in the 
absence or in the presence of the fusion genes (Barr et al., 1999; Tiffin et al., 2003). Thus, unlike 
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down-regulation of the wild-type Pax7, the wild-type Pax3 protein would either be up-regulated 
or unaffected by the expression of fusion proteins. This remains to be examined. 
In
It
 this study, we generated a HEK293 cell line with stable expression of exogenous human 
Pax7 protein. In our system, while the Pax7 expression is decreased by Pax7-FKHR transfection 
in a dose-dependent manner (Fig.5-2B), the mRNA level of Pax7 is not affected (Fig.5-3). It has 
been reported that the endogenous Pax7 mRNA level is decreased markedly in long-term stable 
Pax3-FKHR- or Pax7-FKHR-expressing ERM cells (Tomescu et al., 2004). The discrepancy can 
be explained by the differences of the experimental systems. The exogenous Pax7 protein tested 
in our system is under the control of SV40 promoter, while the expression of the endogenous 
Pax7 in ERM cells is regulated by its natural promoter and is influenced by the tumor cell 
environment. Furthermore, in our system, the introduction of the fusion protein Pax7-FKHR was 
through transient transfection and we examined its short-term effect, while the down-regulation 
of endogenous Pax7 mRNA is more sensitive to the long-term effects of Pax3-FKHR and Pax7-
FKHR proteins. Taken these two factors into consideration, the down-regulation of the wild-type 
Pax7 protein expression by fusion proteins could be at multiple levels, with an mRNA quantity-
dependent mechanism, possibly through the promoter regulation, and an mRNA quantity-
independent inhibition of protein translation. 
 has been suggested that miRNAs can function as either tumor suppressors or oncogenes 
(Esquela-Kerscher and Slack, 2006). A recent comprehensive analysis of miRNA expression 
profiles of 27 sarcomas, including rhobdomyosarcoma, has demonstrated that different 
histological types of sarcoma have distinct miRNA expression patterns (Subramanian et al., 
2008). MicroRNA microarray analysis was performed to determine the effect of oncogenic 
fusion protein Pax7-FKHR on miRNA expression profile (Fig.5-5). To our disappointment, none 
of the predicted miRNAs targeting the short fragment of human Pax7 3’-UTR present in our 
vector was significantly up-regulated by fusion protein expression. However, expression of more 
than twenty miRNAs was significantly increased in fusion protein-transfected cells compared 
with vector- and Pax7-transfected cells. Although 3’-UTR of mRNA is the predominant target 
for miRNAs in mammals, miRNAs can also down-regulate protein expression through 
interaction with the coding region of mRNA. During miRNA recognition, it is essential that the 
~7nt sites in mammalian mRNA match the seed region of miRNA. The possible recognition of 
 108
the coding region of Pax7 mRNA by the up-regulated miRNA candidates is to be further 
explored. 
T
H
C
T
2
he oncogenic fusion protein Pax7-FKHR decreases the wild-type Pax7 protein expression 
without altering the Pax7 mRNA stability. This study provides an insight into the mechanism of 
Pax7-FKHR dominant-negative effect on the wild-type Pax7. As our Pax7 expression system is 
free of its natural promoter regulation and is irresponsive to proteasomal degradation, we 
propose a specific inhibition of Pax7 mRNA translation involving miRNAs. Although the 
expression of the predicted miRNAs targeting the short fragment Pax7 3’-UTR is not increased 
by Pax7-FKHR transfection, whether the significantly up-regulated miRNA candidates target the 
coding region of Pax7 mRNA needs to be determined. 
 
Materials and Methods 
Expression constructs 
uman Pax7(Q+GL-)-pcDNA3 and Pax7-FKHR(Q+GL-)-pcDNA3 expression vectors 
were provided by Dr. Frederic G. Barr (University of Pennsylvania School of Medicine). 
 
Cells 
2C12 and COS7 cells were obtained from American Tissue Culture Collection; HEK293 
cells were purchased from Clontech. C2C12, COS-7 and HEK293 cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) at 37˚C in presence of 5% CO2 under a humidified atmosphere. 
 
Plasmid transfection and selection of stably transfected cells 
ransient transfections were performed using Fugene 6 transfection reagent (Roche 
Applied Science) according to the manufacturer’s protocol, one day after plating cells. Stably 
transfected HEK293 cells were selected for two weeks with 1 mg/ml G418. 
 
Cell treatments 
4 hours after transfection, when cells were 90%-100% confluent, they were treated with 
10 µM MG132 (EMD Biosciences, dissolved in DMSO) or DMSO alone for 10 hours. For the 
mRNA stability experiment, actinomycin D (Sigma, dissolved in DMSO) was added to the 
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culture medium at a concentration of 10 µg/mL to inhibit RNA transcription. Cells were 
harvested at indicated times after addition of actinomycin D and used for total RNA isolations. 
 
Western blotting 
C
C
T
ells were incubated in extraction buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-sulfonyl 
fluoride hydrochloride (AEBSF), 5 µg/ml aprotinin, 5 µg/ml leupeptin, 5 µg/ml pepstatin A, 10 
mM 1,10-phenanthroline) for 15 min at 4˚C. Cell extracts were centrifuged at 21,000xg for 15 
min, and supernatants were resolved by SDS-PAGE and transferred to a nitrocellulose 
membrane. The membranes were blocked in DPBS containing 3% (w/v) dry milk and 0.3% (v/v) 
Tween 20, then incubated with primary antibodies in blocking buffer, followed by incubation 
with horseradish peroxidase-labeled secondary antibodies and detection using the WestPico 
chemiluminescence kit (Pierce). The following primary antibodies were used: mouse anti-Pax7 
(ascites, Developmental Studies Hybridoma Bank, 1:500), rabbit anti-Pax (H-150, Santa Cruz 
Biotechnology, 1:5000), mouse anti-α-tubulin (Sigma, 1:100,000). Secondary antibodies were 
horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG. 
 
Immunofluorescence 
ells grown on coverslips were fixed with 3.7% paraformaldehyde in DPBS for 20 min and 
permeabilized with 0.1% Triton X-100 in DPBS for 5 min. Cells were blocked in DPBS 
containing 5% donkey serum (v/v) and 1% BSA (w/v), then incubated with primary antibody 
mouse anti-Pax7 (supernatant, Developmental Studies Hybridoma Bank, 1:5) diluted in DPBS 
containing 1% BSA, followed by incubation with Rhodamine-RedX-conjugated anti-mouse 
secondary antibody. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Coverslips 
were mounted on slides and examined by Axiovert 200 inverted fluorescent microscope (Zeiss). 
 
Reverse transcription PCR 
otal RNA was extracted using TRIzol Plus RNA purification kit (Invitrogen) according to 
the manufacturer’s protocol. RNA quantity and quality were determined by spectrophotometry. 
For each reaction, 1 µg RNA was treated with DNase I (Invitrogen) at room temperature for 15 
min. cDNA samples were generated with Oligo(dT) using SuperScript III First-Strand Synthesis 
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for RT-PCR kit (Invitrogen). PCR reactions were performed using BIO-X-ACT Short DNA 
Polymerase kit (Bioline). The primer pairs for human Pax7 were 5’-
GCAAGCAGCGACGCAGTCG-3’ (forward) and 5’-GAGAAGTCAGCCTGTGGCT-3’ 
(reverse). The primer pairs for human β-actin were 5’-GCTCGCGTCGACAACGGCTC-3’ 
(forward) and 5’-CAAACATGATCTGGGTCATCTTCT-3’ (reverse). 
 
Real time PCR 
R
T
eal time reactions were performed in 25 µL mixture containing 12.5 µL of iQ SYBR 
Green Supermix (BIO-RAD), 1 µL of each primers (5 µM) and 10.5 µL of 1250 times dilution of 
cDNA preparations from reverse transcription. The primer pairs for human Pax7 were 5’-
CCACAGCTTCTCCAGCTACTCTG-3’ (forward) and 5’-GGGTTGCCCAAGATGCTC-3’ 
(reverse). The primer pairs for human β-actin were 5’- TTGCCGACAGGATGCAGAA-3’ 
(forward) and 5’-GCCGATCCACACGGAGTACT-3’ (reverse). Real time quantifications were 
performed using the BIO-RAD iCycler iQ system. The fluorescence threshold value was 
calculated using iCycler iQ system software. The relative change was calculated using 2−∆∆CT 
method. 
 
MicroRNA microarray 
otal RNA extraction was performed using miRNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. miRNA expression profiling was determined by microRNA microarray 
analysis using 856 human miRNA array probes (version 12.0; LC Sciences, Houston TX). 
ANOVA statistic test was performed to determine the significant changes (p-value < 0.01) of 
different samples. 
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Figure 5-1. Pax7 protein is decreased by co-transfection of Pax7-FKHR in the absence and 
in the presence of a proteasomal inhibitor. C2C12 cells (A and B) or COS7 cells (C) were co-
transfected with human Pax7 expression vector (P) and human Pax7-FKHR expression vector 
(PF), or empty pcDNA3 vector at the indicated amounts (µg). 24 hours after transfection, cells 
were treated with DMSO (A) or 10 µM MG132 (B and C) for 10 hours. Western blotting with 
anti-Pax antibody was performed to show the expression of Pax7-FKHR and Pax7. α-tubulin was 
used as a loading control. Band intensities of Pax7 protein were quantified by densitometry. Data 
represent the mean values ± s.e.m. from three measurements. 
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Figure 5-2. Pax7 protein in stably transfected-HEK293 cells is decreased by Pax7-FKHR 
transfection in a dose-dependent manner. (A) HEK293 cells were transfected with human 
Pax7 expression vector and selected for two weeks in the presence of 1 mg/ml G418. Stably 
transfected HEK293 cells (red) were stained with anti-Pax7 monoclonal antibody. Nuclei (blue) 
were stained with DAPI. (B) HEK293 cells stably transfected with empty vector (HEK293-V), 
or stably expressing Pax7 (HEK293-Pax7) were transiently transfected with Pax7-FKHR 
expression vector (PF), or empty pcDNA3 vector at the indicated amounts (µg). 24 hours after 
transfection, cells were treated with 10 µM MG132 for 10 hours. Western blotting with anti-Pax 
antibody and anti-Pax7 monoclonal antibodies was performed to show the expression of Pax7-
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FKHR and Pax7, respectively. α-tubulin was used as loading control. Band intensities of Pax7 
protein were quantified by densitometry. Data represent the mean values ± s.e.m. from three 
measurements. The experiment was repeated twice with similar results. 
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Figure 5-3. Pax7 mRNA in stably transfected-HEK293 cells is not affected by Pax7-FKHR 
transfection. HEK293 cells stably transfected with empty vector (HEK293-V), or stably 
expressing Pax7 (HEK293-Pax7) were transiently transfected with Pax7-FKHR expression 
vector (PF), or empty vector at the indicated amounts (µg). 24 hours after transfection, cells were 
treated with 10 µM MG132 for 10 hours. Total RNA samples were extracted. (A) After reverse 
transcription, PCR reactions were performed using primer sets for Pax7 and β-actin, respectively. 
Band intensities of Pax7 and β-actin were quantified by densitometry. Data represent the mean 
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values ± s.e.m. from three different experiments. (B) Real time PCR experiments were 
performed using the same cDNA samples as in A. Relative changes were calculated using 2−∆∆CT 
method. Data represent the mean values ± s.e.m. from three different experiments. 
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Figure 5-4. Pax7 mRNA stability is not affected by transfection of Pax7-FKHR. HEK293 
cells stably expressing Pax7 were transiently transfected with empty vector (V-transfected) or 
Pax7-FKHR expression vector (PF-transfected). 24 hours after transfection, cells were treated 
with 10 µM MG132 for 10 hours. Cells were then incubated with actinomycin D (ActD), and 
total RNA samples were collected at 0h, 1h, 2h, 4h and 6h for both vector and fusion protein 
transfected cells. Reverse transcription and PCR reactions were performed. Band intensities of 
Pax7 and β-actin were quantified by densitometry. The amount of Pax7 mRNA was normalized 
to the amount of β-actin. The experiment was repeated twice with similar results. 
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Figure 5-5. Profile of microRNA expression in vector-transfected, Pax7-transfected and 
Pax7-FKHR-transfected HEK293 cells. HEK293 cells were transiently transfected with empty 
vector (C1a), Pax7 expression vector (C2a) or Pax7-FKHR expression vector (Ta). 24 hours after 
transfection, cells were treated with 10 µM MG132 for 10 hours. Total RNA samples were 
extracted and microRNA microarray analysis was carried out by LC Sciences (Houston, TX). 
Each row represents the expression level for a single miRNA and each column represents a 
single repeat of each sample. Each sample has four repeats for a given miRNA. The red or green 
color indicates relatively high or low expression level, respectively. The median of each group 
for a given microRNA is set as 0. The range of relative expression values is from -2.5-fold to 0 
to +2.5-fold. The relative expressions for the miRNAs that changed significantly (ANOVA, p-
value < 0.01) are sorted with a hierarchical clustering analysis. Notice that the miRNAs which 
are red only in Ta samples are the miRNAs up-regulated by transfection of the fusion protein. 
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TT
T
L
he first half of this dissertation is about the cleavage of Notch ligand Dll1 by ADAM 
metalloproteases (Chapter 2) and the effect of Dll1 shedding on muscle cell self-renewal and 
differentiation (Chapter 3). 
he Notch ligand Dll1 undergoes proteolytic cleavage by ADAMs. ADAM10 has been 
implicated in the processing of mouse Dll1. However, proteolytic cleavage of Dll1 in ADAM10-
/- mouse embryonic fibroblasts (MEFs) still amounts to 50% of the processing observed in 
ADAM10+/+ MEFs (Six et al., 2003), suggesting the involvement of other ADAMs in the 
remaining Dll1 processing in ADAM10-/- cells. In our study, the reduction of Dll1 cleavage in 
ADAM9/12/15-/- MEFs indicates that the endogenous ADAM9 or ADAM12 or both are also 
capable of cleaving Dll1 (ADAM15 is not capable of Dll1 processing even when over-
expressed). This study expands the role of ADAMs in processing Notch ligand and suggests their 
function in modulating Notch signaling. 
he Notch pathway is activated upon interaction of a DSL ligand in a signal-sending cell 
with a Notch receptor in a signal-receiving cell, which is known as trans activation. A high level 
of DSL ligand expression in the Notch-expressing cell can inhibit Notch signaling in a cell-
autonomous manner, which is known as cis inhibition. Proteolytic processing of Notch ligand 
Dll1 by ADAM metalloproteases can presumably have dual effects on Notch signaling: down-
regulation of Notch signaling by reducing the ligand availability and up-regulation of Notch 
signaling by relieving the cis inhibition (Fig.6-1). Both effects of ADAM-mediated Dll1 
shedding on Notch signaling have been observed in our studies. 
igand shedding can affect Notch signaling in a cell-autonomous manner. It has been 
reported for mammalian Jagged 1 that the C-terminal fragment of the ligand could compete with 
Notch for γ-secretase and inhibit Notch signaling (LaVoie and Selkoe, 2003). Our results 
demonstrate that the relief of the cis inhibition of Notch mediated by Dll1 outweighs the 
generation of a Dll1 fragment that can compete for γ-secretase cleavage. While co-transfection of 
Dll1 and Notch into the signal receiving cells decreased the Notch signaling due to cis inhibition, 
further co-transfection of Dll1-processing ADAM12 into the signal-receiving cells led to 
activation of Notch. The effect of Notch activation was not observed with a catalytically inactive 
mutant of ADAM12. Furthermore, other ADAMs, including ADAM9 and ADAM17, which 
were capable of Dll1 cleavage, were also capable of relieving Dll1-mediated cis inhibition. In 
contrast, ADAM15, an ADAM that was not involved in Dll1-processing, did not activate Notch 
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signaling. These results show a consistent correlation of Dll1-processing by ADAMs with the 
relief of Dll1-mediated cis inhibition and activation of Notch signaling. Whether Dll1-mediated 
cis inhibition of Notch signaling can be relieved by endogenous ADAM cleavage and whether 
this effect occurs in vivo remains to be determined. 
L
N
N
igand shedding can affect Notch signaling in neighboring cells. RECK (reversion-
inducing cysteine-rich protein with Kazal motifs), a physiological inhibitor of ADAM10, is 
specifically expressed in nestin-positive neural precursor cells (NPCs). RECK decreases the 
ectodomain shedding of Notch ligand by directly inhibiting the proteolytic activity of ADAM10. 
RECK-deficient NPCs undergo precocious differentiation, which is associated with increased 
ADAM10 activity and consequently excessive Dll1 shedding that leads to impaired Notch 
signaling in neighboring cells (Muraguchi et al., 2007). In our study, the soluble catalytically 
inactive extracellular domain of ADAM12, protein X is capable of binding to Dll1 and 
preventing its cleavage by ADAMs, without interfering with Dll1 and Notch interaction in trans. 
Thus, protein X is a dominant-negative modulator reducing Dll1 cleavage by ADAMs. Global 
Notch signaling is elevated in primary myoblast or C2C12 myogenic cells incubated with protein 
X, as indicated by the increased amount of NICD and increased activity of Notch reporter. 
otch signaling acts at multiple steps of muscle development and regeneration process. 
Notch pathway is activated during muscle satellite cell activation and myogenic precursor cell 
expansion in postnatal myogenesis (Conboy and Rando, 2002). Recent genetic evidences suggest 
that Notch signaling initiated by Dll1 and mediated by RBP-J is essential for maintaining a pool 
of myogenic progenitor cells and preventing their differentiation during muscle development 
(Schuster-Gossler et al., 2007; Vasyutina et al., 2007). This is consistent with our findings that 
inhibition of Notch signaling decreases the expression of muscle satellite cell marker, Pax7, 
while stimulation of Notch signaling expends the pool of Pax7+ cells. 
otch has been implicated in asymmetric cell division. It has been reported that 
Pax7+Myf5- satellite cell undergoes asymmetric cell division perpendicular to the muscle fiber, 
and generates a basal Pax7+Myf5- cell contributing to the satellite cell reservoir and an apical 
Pax7+Myf5+ cell exhibiting precocious differentiation. The two daughter cells show asymmetric 
expression of Dll1, with higher Dll1 level and low Notch activity in the committed Pax7+Myf5+ 
cell (Kuang et al., 2007). In our study, we have utilized cultured satellite cells in vitro and they 
are deprived of niche regulation. The modulation of Notch signaling among cultured cells in 
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vitro may be achieved by stochastic mechanisms (Losick and Desplan, 2008). We propose that 
one of the mechanisms involves the proteolytic processing of Dll1 by ADAM proteases. Dll1 
shedding helps establish a balance between Pax7+MyoD+ and Pax7+MyoD- cells after exit from 
the cell cycle. Proteolytic processing of Dll1 by ADAM proteins in some cells leads to ligand 
depletion and down-regulation of Notch signaling in neighboring cells. Cells in which Dll1 
cleavage takes place would acquire higher level of Notch activity than their neighbors, leading to 
down-regulation of MyoD. Cells in which the cleavage of Dll1 does not occur efficiently would 
attain lower level of Notch signaling and maintain MyoD expression. 
T
P
P
he second half of this dissertation is about the mechanism of Pax7 functioning as a key 
regulator of muscle satellite cell survival (Chapter 4) and the decreased Pax7 protein with 
expression of Pax7-FKHR fusion protein generated by a specific chromosomal translocation in 
rhabdomyosarcoma (Chapter 5). 
ax7 is essential for maintenance of muscle satellite cells. In skeletal muscle of Pax7 
knockout mice, satellite cells are present, but exist in reduced numbers during postnatal 
development (Oustanina et al., 2004). This is due to the anti-apoptotic function of Pax7, which 
cannot be compensated by its paralogue, Pax3 (Relaix et al., 2006). The heterozygous MnSOD 
knockout mice exhibit increased oxidative damage and incidence of apoptosis (Van et al., 2001), 
suggesting a critical role of MnSOD in cell survival. Our goal was to explore the potential and 
the mechanism of MnSOD-mediating Pax7 anti-apoptotic function. The up-regulation of 
MnSOD by Pax7 at the transcriptional level provides an insight into the capacity of MnSOD in 
mediating Pax7 function. However, whether MnSOD is indispensible for Pax7-regulated satellite 
cell survival needs to be further addressed. The up-regulation of MnSOD by Pax7 is not 
dependent on FOXO proteins, which are well-known positive regulators of MnSOD promoter. A 
recent study identified a consensus DNA sequence, GTCAC, which is recognized by Pax7 and 
mediates the Pax7 binding directly (White et al., 2008). We have analyzed the Pax7 binding sites 
in MnSOD promoter, but they are not required for Pax7-mediated activation. The question how 
Pax7 up-regulates MnSOD promoter remains open and possible co-factors and key elements 
await for identification. 
ax7 is involved in a chromosomal translocation that leads to alveolar rhabdomyosarcoma 
(ARM). The chromosomal translocation fuses the Pax7 gene on chromosome 1 to the FKHR 
gene on chromosome 13 and generates an oncogenic fusion protein Pax7-FKHR. It has been 
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observed that the wild-type Pax7 is down-regulated in fusion positive ARM tumors (Tiffin et al., 
2003), and in Pax-FKHR expressing ERM cell lines (Tomescu et al. 2004), implicating that 
fusion proteins have a dominant-negative effect on the wild-type Pax7 in order to circumvent the 
possible competition and to impair the normal Pax7 protein function. Consistent with previous 
findings, our results show that expression of the wild-type Pax7 protein is down-regulated upon 
transfection of Pax7-FKHR fusion protein in HEK293 cells stably expressing exogenous Pax7. 
This down-regulation is independent of Pax7 promoter regulation and cannot be diminished by 
application of proteasomal inhibitor. As the Pax7 mRNA level is not affected by fusion protein 
transfection, we propose a specific inhibition of Pax7 mRNA translation involving microRNAs. 
A recent comprehensive analysis of miRNA expression profiles of 27 sarcomas, including 
rhobdomyosarcoma, has demonstrated that different histological types of sarcoma have distinct 
miRNA expression patterns (Subramanian et al., 2008). Although in fusion protein-transfected 
cells, the predicted miRNAs targeting the 3’-UTR of Pax7 do not appear to be significantly up-
regulated, as revealed by microRNA expression profiling, the potential of the up-regulated 
miRNA candidates in blocking the translation of Pax7 mRNA needs to be examined. 
In conclusion, this dissertation provides insights into the proteolytic processing of Notch 
ligand 
not be cleaved by ADAM 
metallo
by ADAM metalloproteases and the effect of ligand shedding on Notch signaling and on 
muscle cell self-renewal and differentiation. This dissertation also sheds light on the mechanism 
of Pax7-mediated muscle satellite cell survival and the dominant-negative effect on the wild-type 
Pax7 by oncogenic fusion protein Pax7-FKHR in rhabdomyosarcoma. 
For future studies, a mouse model with a mutated Dll1, which can
proteases should be generated. The effect of Dll1 shedding on Notch signaling and on 
myogenic differentiation in vivo could be assessed more accurately with this non-cleavable Dll1 
knock-in mutant. Other mediators of the up-regulation of MnSOD by Pax7 should be identified 
and the requirement of MnSOD for Pax7-mediated cell survival should be determined. The 
involvement of the miRNAs up-regulated by fusion protein in decreasing the wild-type Pax7 
expression should be examined and the potential of the miRNAs as a target for 
rhabdomyosarcoma treatment should be evaluated. 
 127
References 
 
Conboy IM, Rando TA. (2002) The regulation of Notch signaling controls satellite cell 
activation and cell fate determination in postnatal myogenesis. Dev Cell. 3, 397-409. 
 
Kuang S, Kuroda K, Le Grand F, Rudnicki MA. (2007) Asymmetric self-renewal and 
commitment of satellite stem cells in muscle. Cell. 129, 999-1010. 
 
LaVoie MJ, Selkoe DJ. (2003) The Notch ligands, Jagged and Delta, are sequentially processed 
by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. J Biol Chem. 
278, 34427-34437. 
 
Losick R, Desplan C. (2008) Stochasticity and cell fate. Science. 320, 65-68. 
 
Muraguchi T, Takegami Y, Ohtsuka T, Kitajima S, Chandana EP, Omura A, Miki T, 
Takahashi R, Matsumoto N, Ludwig A, Noda M, Takahashi C. (2007) RECK modulates 
Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat Neurosci. 10, 
838-845. 
 
Oustanina S, Hause G, Braun T. (2004) Pax7 directs postnatal renewal and propagation of 
myogenic satellite cells but not their specification. EMBO J. 23, 3430-3439. 
 
Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, Rocancourt D, Tajbakhsh S, 
Mansouri A, Cumano A, Buckingham M. (2006) Pax3 and Pax7 have distinct and overlapping 
functions in adult muscle progenitor cells. J Cell Biol. 172, 91-102. 
 
Schuster-Gossler K, Cordes R, Gossler A. (2007) Premature myogenic differentiation and 
depletion of progenitor cells cause severe muscle hypotrophy in Delta1 mutants. Proc Natl Acad 
Sci U S A. 104, 537-542. 
 
Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, Logeat F. (2003) The Notch 
ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. Proc Natl 
Acad Sci U S A. 100, 7638-7643. 
 
Subramanian S, Lui WO, Lee CH, Espinosa I, Nielsen TO, Heinrich MC, Corless CL, Fire 
AZ, van de Rijn M. (2008) MicroRNA expression signature of human sarcomas. Oncogene. 27, 
2015-2026. 
 
Tiffin N, Williams RD, Shipley J, Pritchard-Jones K. (2003) PAX7 expression in embryonal 
rhabdomyosarcoma suggests an origin in muscle satellite cells. Br J Cancer. 89, 327-332. 
 
Tomescu O, Xia SJ, Strezlecki D, Bennicelli JL, Ginsberg J, Pawel B, Barr FG. (2004) 
Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR 
fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab Invest. 84, 1060-1070. 
 
 128
Van Remmen H, Williams MD, Guo Z, Estlack L, Yang H, Carlson EJ, Epstein CJ, Huang 
TT, Richardson A. (2001) Knockout mice heterozygous for Sod2 show alterations in cardiac 
mitochondrial function and apoptosis. Am J Physiol Heart Circ Physiol. 281, H1422-1432. 
 
Vasyutina E, Lenhard DC, Wende H, Erdmann B, Epstein JA, Birchmeier C. (2007b) RBP-
J (Rbpsuh) is essential to maintain muscle progenitor cells and to generate satellite cells. Proc 
Natl Acad Sci U S A. 104, 4443-4448. 
 
White RB, Ziman MR. (2008) Genome-wide discovery of Pax7 target genes during 
development. Physiol Genomics. 33, 41-49. 
 129
 
Figure 6-1. Dll1 shedding by ADAM metalloproteases has dual effects on Notch signaling. 
Proteolytic cleavage of Dll1 by ADAM metalloproteases in the signal-sending cell leads to 
reduced ligand availability and down-regulation of Notch signaling in the neighboring cell 
(upper panel). Proteolytic cleavage of Dll1 by ADAM metalloproteases in the signal-receiving 
cell leads to relief of cis inhibition and up-regulation of Notch signaling in a cell-autonomous 
manner (lower panel). 
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